

2

Insulin Action

*Molecular Mechanisms
and Determinants of Specificity*

*Michael J. Quon, MD, PHD
and Simeon I. Taylor, MD, PHD*

CONTENTS

INTRODUCTION
INSULIN SIGNALING FOLLOWS PARADIGM FOR
RTK SIGNAL TRANSDUCTION
INSULIN SIGNALING PATHWAYS THAT
REGULATE GLUCOSE TRANSPORT
MECHANISMS FOR ACHIEVING SPECIFICITY
SUMMARY
REFERENCES

INTRODUCTION

Insulin is a peptide hormone that plays critical roles in the regulation of growth, differentiation, and metabolism. The physiological importance of insulin is underscored by the fact that the insulin receptor has been evolutionarily conserved and is found in organisms ranging from *Drosophila* to humans. Furthermore, insulin-dependent diabetes mellitus, a disease characterized by absolute insulin deficiency, was a uniformly fatal condition before the advent of insulin therapy. Like other circulating polypeptide hormones, insulin initiates its biological actions by binding to specific cell-surface receptors. The molecular cloning of the insulin receptor led to the discovery that it belongs to a large family of ligand-activated receptor tyrosine kinases (RTKs) that includes receptors for many other growth factors (1–5). Many of the molecules involved with the transduction of signals from a multitude of RTKs also participate in insulin signaling. One of the central puzzles in the field of signal transduction is understanding how signal specificity is achieved after the interaction of the ligand with its receptor since so many postreceptor events seem to be shared in common by a variety of different RTKs. In this chapter, we briefly review the current understanding of how insulin receptor signaling follows a general paradigm for RTK signal transduction. Particular emphasis is given to signaling pathways related to glucose transport since this is among the most important physiological actions of insulin and is a specialized metabolic function that

From: *Gene Engineering and Molecular Models in Endocrinology*
Edited by: Margaret A. Shupnik © Humana Press Inc., Totowa, NJ

distinguishes the insulin receptor from other RTKs. Finally, we discuss several potential mechanisms for achieving signal specificity that are illustrated by recent studies relevant to insulin signaling.

INSULIN SIGNALING FOLLOWS PARADIGM FOR RTK SIGNAL TRANSDUCTION

As illustrated in Fig. 1, the propagation of information resulting from the binding of insulin to its cell surface receptor follows a general paradigm for RTK signal transduction that ultimately culminates in multiple biological effects, including increased glucose transport, gene and enzyme regulation, and mitogenesis, that are important for the regulation of metabolism and growth.

Ligand Binding and Receptor Dimerization

The first step in initiating signal transduction by an RTK involves the specific binding of a ligand to the extracellular portion of its cognate cell-surface receptor. In the case of monomeric receptors such as the epidermal growth factor (EGF) receptor, ligand binding results in receptor dimerization, a necessary first step in signal transduction (4,6,7). The insulin receptor has a heterotetrameric structure (actually, a dimer of $\alpha\beta$ heterodimers) consisting of two extracellular α -subunits and two transmembrane β -subunits joined by disulfide bonds (8). Thus, even in the absence of ligand, the insulin receptor exists in a dimeric form. The α -subunit of the insulin receptor contains fibronectin III repeats and cysteine-rich domains that are also found in several other RTKs. Insulin binds with high affinity to specific regions of the α -subunit (including the cysteine-rich domain), resulting in a rapid conformational change in the receptor (9,10). In the absence of ligand, the α -subunit of the insulin receptor appears to exert a tonic inhibitory influence on insulin receptor function because insulin receptors that have had the α -subunit removed by trypsin digestion or expression of the cytoplasmic domain of the insulin receptor alone results in constitutive activation of receptor signaling (11,12).

Receptor Autophosphorylation and Activation of Intrinsic Tyrosine Kinase

Ligand binding and receptor dimerization result in activation of the RTK. The kinase region of all RTKs shares substantial homology in both the adenosine triphosphate binding site and the catalytic domain (4). The kinase of one half of the receptor dimer phosphorylates cytoplasmic tyrosine residues on the other half of the receptor dimer. This mutual transphosphorylation event is known as receptor autophosphorylation and results in a large increase in the catalytic activity of the receptor. The β -subunit of the human insulin receptor contains tyrosine residues distal to the catalytic domain at positions 1158, 1162, and 1163 (in the so-called activation loop) that undergo autophosphorylation and are important for enhancing the tyrosine kinase activity of the receptor (13–15).

Tyrosine Phosphorylation of Cellular Substrates and Recruitment of Distal Signaling Molecules

Activation of the RTK leads to tyrosine phosphorylation of cellular substrates that propagate signaling. In addition, receptor autophosphorylation enables the RTK to




Fig. 1. Insulin signal transduction follows paradigm for RTK signaling.

directly engage signaling molecules via interactions between phosphotyrosine motifs on the receptor and src homology-2 (SH2) domains on downstream molecules. SH2 domains are protein domains of ~100 amino acids that share homology with a noncatalytic region of the src protooncogene product. Many molecules involved with RTK signaling, including src, phosphatidylinositol 3-kinase (PI3K), growth factor receptor-bound protein 2 (GRB-2), SH2-containing phosphatase-2 (SHP-2), GTPase-activating protein (GAP), and phospholipase C- γ (PLC- γ), contain SH2 domains. Motifs defined by the three amino acid residues on the C-terminal side of the phosphotyrosine residue provide specificity for interaction with particular SH2 domains (16,17). In the case of receptors for EGF and platelet-derived growth factor (PDGF), the particular phosphotyrosine sites that engage specific SH2 domains of various signaling molecules have been well mapped (18,19).

Although the autophosphorylated insulin receptor β -subunit is capable of directly interacting with molecules such as PI3K, SHP-2, and GAP (20–22), direct binding of phosphotyrosine motifs on the insulin receptor with SH2 domain-containing molecules does not appear to be the major pathway for insulin signal transduction. Instead, there are substrates of the insulin receptor tyrosine kinase such as insulin receptor substrate-1 (IRS-1), IRS-2, IRS-3, IRS-4, SHC, and GRB-2-associated binder-1 (GAB-1) that provide an interface between the insulin receptor and downstream SH2 domain-containing molecules (23–29). The IRS family of proteins contain a number of conserved regions including a pleckstrin homology (PH) domain and a phosphotyrosine binding domain that are important for the ability of the autophosphorylated insulin receptor to interact with and phosphorylate IRS molecules (23,30,31). In addition, these insulin receptor substrates contain multiple phosphotyrosine motifs that can bind to SH2 domains and may serve as docking molecules that mediate the formation of signaling complexes consisting of several SH2 domain-containing proteins.

Signaling Proteins Containing SH2 and SH3 Domains

Many of the signaling molecules participating in RTK signal transduction pathways contain SH2 and/or SH3 domains that mediate protein-protein interactions. As mentioned previously, SH2 domains interact specifically with phosphorylated tyrosine motifs. SH3 domains bind with high affinity to particular proline-rich sequences (4). Some SH2 domain-containing proteins (e.g., SHP-2, PLC- γ) are effector molecules that possess intrinsic catalytic activity that is regulated or localized by interactions of the SH2 domain of the effectors with phosphotyrosine motifs on other proteins (e.g., IRS-1). Other SH2/SH3 domain-containing proteins (e.g., GRB-2, Nck, and the p85 regulatory subunit of PI3K) are known as adaptor proteins because they have no intrinsic catalytic activity and their function involves forming specific signaling complexes mediated by the simultaneous interactions of multiple SH2/SH3 domains on the adaptor protein with both upstream and downstream signaling molecules. Activation of Ras and PI3K, two major effector pathways common to a number of growth factor receptors including the insulin receptor, fit this latter pattern. For example, GRB-2 is normally prebound to SOS (a guanine nucleotide exchange factor) via interactions of the two SH3 domains of GRB-2 and proline-rich regions of SOS. When phosphotyrosine motifs on IRS-1 and Shc interact with the SH2 domain of GRB-2, activation of the prebound SOS promotes formation of the GTP-bound form of Ras, leading to activation of Ras. Similarly, the p85 regulatory subunit of PI3K is normally preassociated with the p110

catalytic subunit. Insulin stimulation results in the interaction of phosphotyrosine motifs on IRS proteins with SH2 domains on p85, leading to activation of the prebound p110 catalytic subunit (for reviews see refs. 32 and 33).

Downstream Phosphorylation Cascades

Distal RTK signaling pathways are difficult to dissect cleanly because multiple branching pathways begin to emerge from single effectors. Adding to the complexity, multiple upstream inputs often converge on single branch points. Furthermore, negative feedback mechanisms sometimes exist that lead to downstream signals affecting upstream components. However, it is clear that various serine/threonine phosphorylation cascades contribute to the propagation of signaling from the cell surface to the nucleus. These phosphorylation cascades seem to be common to signaling for many growth factors including insulin. For example, Ras directly activates Raf, a serine/threonine kinase that phosphorylates and activates MEK, which in turn phosphorylates and activates mitogen-activated protein kinase (MAPK), leading to induction and activation of early immediate genes such as the protooncogenes *c-jun* and *c-fos*. Insulin signaling mediated by PI3K pathways also involves downstream serine/threonine kinase cascades. For example, phospholipid products generated by PI3K activate PDK1, a serine/threonine kinase that phosphorylates and activates Akt (another serine/threonine kinase), which in turn phosphorylates and inactivates glycogen synthase kinase-3 (GSK-3) (34–36). This process results in activation of glycogen synthase and the stimulation of glycogen synthesis.

Protein Tyrosine Phosphatases

Since tyrosine phosphorylation is critical to initiating and propagating signaling by RTKs, it is not surprising that dephosphorylation of tyrosine residues by protein tyrosine phosphatases (PTPases) contributes to the regulation of signaling. The number and diversity of PTPases rivals that of the RTKs (37,38). PTPases are generally subdivided into a family of nontransmembrane proteins containing a single catalytic PTPase domain and a family of transmembrane receptor-like PTPases that typically contain tandem PTPase domains. The transmembrane PTPases (also known as receptor-like PTPases) have been further categorized into eight groups based on shared structural features of various extracellular domains (38). The large number of PTPases discovered and characterized to date suggests that each PTPase plays a specific role in modulating signaling by RTKs. PTPases such as SHP-2 contain SH2 domains that confer specificity whereas the receptor-like PTPases have extracellular domains that presumably interact with specific ligands. In addition, subcellular localization of particular PTPases may contribute to their specificity. Although all of the determinants of PTPase specificity are not understood, there is evidence that particular PTPases show selectivity for specific RTKs (39).

In the case of signaling by the insulin receptor, the transmembrane PTPases, PTP- α , PTP- ϵ , and LAR, have all been implicated as modulators of insulin action (40–42). In particular, LAR has been shown to interact with and dephosphorylate the insulin receptor in intact cells (43). In addition, the expression and level of activity of LAR in insulin targets such as muscle and adipose tissue is increased in insulin-resistant states such as obesity and diabetes (44,45). Among the nontransmembrane PTPases, PTP1B and SHP-2 have both been shown to modulate insulin signaling. PTP1B dephos-

phorylates the insulin receptor both in vitro and in intact cells (39,46,47). In addition, PTP1B regulates both mitogenic and metabolic actions of insulin (41,48,49). In tissue culture models, an increase in the level and activity of PTP1B has been associated with insulin resistance induced by exposure to high glucose levels. In addition, the level and activity of PTP1B in human skeletal muscle is positively correlated with in vivo measures of insulin sensitivity (50–52). Binding of the SH2 domains of SHP-2 to phosphotyrosine motifs on either the insulin receptor or IRS-1 results in activation of SHP-2 PTPase activity (53,54). Interestingly, a number of studies have shown that SHP-2 participates in Ras- and MAPK-dependent pathways as a positive mediator of mitogenic actions of insulin and other growth factors (55–58).

INSULIN SIGNALING PATHWAYS THAT REGULATE GLUCOSE TRANSPORT

A primary metabolic function of insulin that distinguishes it from other growth factors is the promotion of whole-body glucose utilization and disposal. The rate-limiting step in glucose utilization under normal conditions is glucose transport into cells. The insulin-responsive glucose transporter GLUT4 is expressed at high levels almost exclusively in classical insulin targets such as muscle and adipose tissue (for a review see ref. 59). Insulin stimulates increased glucose transport in these tissues by causing the redistribution of GLUT4 from an intracellular pool to the cell surface, where it acts as a facilitative transporter to enhance entry of glucose into the cell (60–62). This redistribution of GLUT4 is due largely to insulin increasing the rate of exocytosis of GLUT4 (insulin may also have a minor effect in decreasing endocytosis of GLUT4) (63–65).

Although the tissue-specific distribution of GLUT4 and the effects of insulin on the subcellular localization of GLUT4 have been known for some time, elucidation of metabolic insulin signaling pathways has lagged behind other areas of insulin signal transduction for several reasons. First, although muscle and adipose tissue normally express high levels of GLUT4 and are extremely responsive to insulin stimulation, the ability to apply modern molecular methods such as transfection of recombinant DNA to these terminally differentiated tissues has been limited. Second, tissue culture models of muscle and adipose cells that are easier to manipulate (e.g., 3T3-L1 adipocytes, L6 myocytes, or C2C12 cells) do not always faithfully reflect important characteristics of bona fide insulin target cells. For example, the relative levels of expression of IRS-1, -2, and -3 are quite different in primary adipose cells and 3T3-L1 adipocytes (25,66,67). Third, the requisite cellular machinery for appropriate subcellular trafficking of GLUT4 seems to be lacking in commonly used tissue culture cells such as NIH-3T3 fibroblasts, Chinese hamster ovary cells, or COS cells, which do not normally express GLUT4. Therefore, even when recombinant insulin receptors and GLUT4 are stably expressed in these cells, they are much less responsive to insulin than muscle or adipose cells (68).

The recent use of electroporation to transfect adipose cells in primary culture in conjunction with quantitative methods for assessment of cell surface GLUT4 has led to a clearer understanding of metabolic insulin signaling pathways (41,69–75). In addition, transgenic mice that have had key signaling molecules either knocked out or overexpressed have provided valuable insights (76–80). Finally, microinjection or viral

transfection strategies in differentiated 3T3-L1 adipocytes along with semiquantitative methods for assessing cell surface GLUT4 have also been informative (81–85). Figure 2 summarizes some of what is currently known about insulin signaling pathways related to the translocation of GLUT4 in adipose cells.

Since insulin receptor autophosphorylation and enhancement of RTK activity are among the earliest known events in insulin signaling, one might predict that RTK activity is necessary for most, if not all, biological actions of insulin including metabolic actions such as recruitment of GLUT4 to the cell surface. This idea was supported by the identification of kinase-deficient insulin receptor mutants in some patients with syndromes of extreme insulin resistance (86). Direct evidence that insulin RTK activity is important for mediating the effect of insulin to stimulate translocation of GLUT4 in insulin target cells has been obtained using transfected rat adipose cells in primary culture (Fig. 3) (70). Cells overexpressing wild-type insulin receptors showed a marked increase in cell surface GLUT4 in the absence of insulin when compared with control cells transfected with an empty expression vector. In contrast, cells overexpressing a kinase-deficient mutant insulin receptor had an insulin dose-response curve similar to that of the control cells. Taken together, these data suggest that intact RTK activity is necessary to mediate signaling from the insulin receptor to translocation of GLUT4. Furthermore, it is likely that unoccupied insulin receptors have a low level of intrinsic tyrosine kinase activity whose signal is proportional to the amount of receptors expressed. Additional evidence that the insulin RTK is important in metabolic signaling comes from studies on PTPases such as LAR and PTP1B that are known to dephosphorylate the insulin receptor. Both of these PTPases have been implicated in the negative regulation of metabolic signaling by insulin (39,41,43,45–47,49). In particular, overexpression of PTP1B in rat adipose cells leads to a significant decrease in the level of GLUT4 at the cell surface in both the absence and presence of insulin (41). The fact that PTP1B decreases cell surface GLUT4 in the absence of insulin provides further support for the idea that a small signal is generated by the intrinsic tyrosine kinase activity of unoccupied receptors.

Downstream from the insulin RTK, a number of insulin receptor substrates play roles in insulin-stimulated translocation of GLUT4. Overexpression of IRS-1 in transfected rat adipose cells leads to an increase in cell-surface GLUT4 in the absence of insulin similar to that seen with overexpression of the insulin receptor (71). Interestingly, transfection of adipose cells with an antisense ribozyme against IRS-1 results in a decrease in insulin sensitivity without a decrease in maximal responsiveness with respect to translocation of GLUT4 (71). Thus, although IRS-1 is capable of mediating the effect of insulin to stimulate translocation of GLUT4, other parallel pathways are probably involved. Indeed, the fact that transgenic IRS-1 knockout mice are only mildly insulin resistant provides unequivocal evidence that IRS-1 contributes to metabolic actions of insulin but is not absolutely required for insulin-stimulated glucose uptake (76,77). Overexpression of IRS-2 (74) and IRS-3 (143) in rat adipose cells also leads to translocation of GLUT4 in the absence of insulin, suggesting that these substrates may also contribute to metabolic actions of insulin. Of note, in adipose cells, the time course for the association of IRS-3 with the p85 regulatory subunit of PI3K in response to insulin stimulation is much more rapid than for IRS-1 (87). In addition, the magnitude of the association between IRS-3 and p85 in response to insulin seems to be greater than for IRS-1. Furthermore, in transgenic mice lacking IRS-1, IRS-3 is the insulin




Fig. 2. Insulin signaling pathways that contribute to translocation of GLUT4 in adipose cells. Interestingly, although activation of PI3K is necessary for insulin-stimulated translocation of GLUT4, it does not appear to be sufficient because activation of PI3K by PDGF is without effect on translocation of GLUT4 when PDGF receptors are expressed at physiological levels.




Fig. 3. Insulin RTK activity is important for insulin-stimulated translocation of GLUT4. Rat adipose cells were cotransfected with an epitope-tagged GLUT4 and wild-type human insulin receptors (▲), tyrosine kinase-deficient mutant insulin receptors cells (■), or an empty expression vector (control) (●). Cell-surface concentrations of epitope-tagged GLUT4 are shown as a function of insulin concentration (expressed as a percentage of the maximally stimulated control cells) (70).

receptor substrate in adipose cells responsible for the majority of activation of PI3K in response to insulin (87,88). Since PI3K is necessary for insulin-stimulated glucose transport (*see* the next paragraph), these data suggest that IRS-3 may be a major insulin receptor substrate mediating metabolic actions *in vivo*.

As already mentioned, two major insulin signaling pathways downstream from the receptor substrates are the PI3K- and the Ras-dependent pathways. Overexpression of constitutively active mutants of either PI3K or Ras in adipose cells leads to massive recruitment of GLUT4 to the cell surface in the absence of insulin (72,89). However, overexpression of recombinant proteins can sometimes lead to effects that do not occur under physiological conditions. Interestingly, when dominant inhibitory mutants were used to knock out either endogenous PI3K or Ras in adipose cells, overexpression of the PI3K mutant resulted in a nearly complete inhibition of insulin-stimulated translocation of GLUT4 (Fig. 4) whereas overexpression of the Ras mutant did not cause a significant change in the insulin dose-response curve (72). Thus, even though constitutively active PI3K and Ras are both capable of stimulating the recruitment of GLUT4 to the cell surface, it appears that only PI3K plays a necessary physiological role in this process. However, PI3K activity *per se* is not sufficient to cause translocation of GLUT4 because stimulation of PI3K activity in adipose cells using other growth factors such as PDGF does not result in translocation of GLUT4 (73,90).




Fig. 4. PI3K is necessary for insulin-stimulated translocation of GLUT4. Rat adipose cells were cotransfected with an epitope-tagged GLUT4 and either a dominant inhibitory mutant of the p85 regulatory subunit of PI3K (▲) or an empty expression vector (control) (●). Cell-surface concentrations of epitope-tagged GLUT4 are shown as a function of insulin concentration (expressed as a percentage of the maximally stimulated control cells) (72). Data represent insulin dose response for an average of four experiments.

There are several effectors downstream of PI3K that may play a role in insulin-stimulated translocation of GLUT4. Akt is a serine/threonine kinase that is activated by insulin via lipid products of PI3K binding to the PH domain of Akt, and phosphorylation of critical serine and threonine residues on Akt by phosphoinositide-dependent kinase-1, another kinase downstream of PI3K that is activated by lipid products of PI3K (34,91,92). Like PI3K and Ras, overexpression of constitutively active mutants of Akt in rat adipose cells or 3T3-L1 adipocytes leads to massive recruitment of GLUT4 to the cell surface (75,84). However, in contrast to PI3K, dominant inhibitory mutants of Akt that are kinase deficient only partially inhibit insulin-stimulated translocation of GLUT4 in adipose cells (Fig. 5). This suggests the possibility that multiple downstream effectors of PI3K contribute to mediating the translocation of GLUT4. For example, the atypical PKC isoform PKC- ζ is a good candidate for another downstream effector of PI3K that may contribute to metabolic signaling by insulin. In 3T3-L1 adipocytes, overexpression of a constitutively active PKC- ζ mutant increased glucose transport whereas overexpression of a dominant inhibitory PKC- ζ mutant decreased insulin-stimulated glucose transport (93).

In addition to the progress being made by tracing signaling pathways starting from




Fig. 5. Physiological role for Akt in insulin-stimulated translocation of GLUT4. Rat adipose cells were cotransfected with an epitope-tagged GLUT4 and wild-type Akt (●), a kinase inactive mutant Akt (▲), or an empty expression vector (control) (○). Cell-surface concentrations of epitope-tagged GLUT4 are shown as a function of insulin concentration (expressed as a percentage of the maximally stimulated control cells) (75).

the insulin receptor, progress has also been made in understanding the molecular mechanisms underlying the subcellular trafficking of GLUT4 from an intracellular compartment to the cell surface in response to insulin. Mechanisms common to vesicular trafficking during regulated exocytosis of synaptic vesicles in neurons also apply to the subcellular localization of GLUT4. In general, vesicle docking and fusion to the plasma membrane is mediated by specific interactions of soluble *N*-ethylmaleimide-

sensitive factor attachment protein receptors (SNAREs) (94). v-SNARE proteins are localized to the vesicle membrane and t-SNARE proteins are localized to the target plasma membrane. There is good evidence that specific isoforms of v-SNARE and t-SNARE molecules are involved with GLUT4 trafficking (for a review see ref. 95). For example, VAMP2 (a v-SNARE) is localized to GLUT4-containing vesicles in adipose cells and appears to participate in insulin-stimulated exocytosis of GLUT4 (96–98). Syntaxin 4 (a t-SNARE) binds specifically to VAMP2 and is localized to the plasma membrane in muscle and adipose cells. Furthermore, insulin-stimulated translocation of GLUT4 in 3T3-L1 adipocytes can be blocked by using antibodies against Syntaxin 4 or overexpressing the cytoplasmic tail of Syntaxin 4 (98–100). Presumably, the signaling pathways leading from the insulin receptor interface at some point with the vesicular trafficking machinery for GLUT4. An important goal of current investigations related to metabolic actions of insulin is to identify and characterize direct interactions between signaling proteins and trafficking machinery.

MECHANISMS FOR ACHIEVING SPECIFICITY

Although insulin signaling follows a general paradigm for signaling by RTKs and many downstream signaling components are shared in common with other RTK signaling pathways, the biological actions resulting from insulin stimulation such as increased glucose transport are quite specific and distinctive. At each step in the signal transduction pathway, there are opportunities and potential mechanisms for incorporating signal specificity. Here we briefly discuss selected examples that illustrate potential mechanisms that may be used to achieve specificity in insulin signaling.

Specificity at the Receptor Level

The binding affinity between insulin and its receptor is quite high and provides an obvious first determinant of signal specificity. However, insulin is also capable of binding and activating other related receptors such as the insulin-like growth factor-1 (IGF-1) receptor. Similarly, IGF-1 is capable of binding and activating the insulin receptor (101). Furthermore, because the insulin receptor and IGF-1 receptor are homologous, the formation of hybrid receptors with an insulin receptor $\alpha\beta$ -subunit joined to an IGF-1 $\alpha\beta$ -subunit can occur. These hybrid receptors are capable of undergoing transphosphorylation and may generate unique signals. Since the relative amounts of insulin receptors and IGF-1 receptors differ in particular tissues, the numbers of pure receptors and hybrid receptors may vary from tissue to tissue. Although the binding affinities of insulin and IGF-1 for the heterologous receptor are approx 100-fold less than for their own receptor, the integration of multiple signals at different amplitudes may contribute to the determination of specific effects. For example, in vascular endothelial cells that normally express 10 times as many IGF-1 receptors as insulin receptors, stimulation with insulin at concentrations sufficient to saturate both IGF-1 and insulin receptors results in the production of nitric oxide at a level twice that seen with stimulation by IGF-1 at comparable concentrations (102). Additional evidence that the binding interaction between ligand and receptor affects signaling specificity comes from studies with point mutants of insulin molecules that have been designed to have higher binding affinities for the insulin receptor than the native insulin molecule. For

example, the Asp B10 insulin mutant has a much higher binding affinity than native insulin for the insulin receptor and appears to favor mitogenic rather than metabolic actions of insulin (103). Another feature of insulin binding to its receptor that may affect signal specificity is the fact that insulin binding exhibits negative cooperativity (104). That is, the binding affinity of insulin for its receptor decreases with increasing insulin concentrations. Thus, the dynamics of intracellular signaling events in response to a particular insulin secretory profile may encode some specificity. Finally, integration of signals generated by cross talk between different types of receptors may contribute to the specificity of insulin signaling. For example, in addition to the well-known cross talk that occurs between insulin and IGF-1 at the receptor level, there is evidence for cross talk between insulin and PDGF signaling with respect to interactions between IRS-1 and PI3K (105). Furthermore, recent evidence suggests that activation of G-protein-coupled receptors such as the angiotensin II receptor can influence insulin signaling through interactions with IRS-1 and -2 (106–108).

Specificity at the Receptor Substrate Level

The existence of multiple substrates of the insulin receptor also provides opportunities to incorporate specificity. Members of the IRS family of substrates contain multiple phosphotyrosine docking sites for SH2 domain-containing proteins. The number of these docking sites and the particular SH2 domains with which they interact vary among the different IRS proteins. That is, the combination of downstream signaling molecules engaged by an IRS protein as well as the relative affinities of particular downstream effectors for each substrate are unique for each IRS protein. Thus, tissue-specific differences in the relative expression levels of these IRS substrates may result in formation of distinct signalling complexes in particular tissues and help explain why some actions of insulin predominate in certain tissues (66,109). In addition, in some downstream signaling molecules containing tandem SH2 domains (e.g., SHP-2 and the p85 regulatory subunit of PI3K), the spatial relationship between these SH2 domains provides an additional level of specificity. That is, the geometry of multiple phosphotyrosine motifs on a particular substrate is important for optimal binding and activation of proteins with tandem SH2 domains (110,111). Similarly, the relationship of SH2 and SH3 domains in various adaptor or effector molecules may impose physical constraints on the formation of signaling complexes that are important for signal specificity.

In addition to members of the IRS family, there are other substrates of the insulin receptor that are also expressed in a tissue-specific manner and may contribute to specificity in insulin signaling. For example, there is a family of M_r 120,000 integral membrane glycoproteins that are phosphorylated by the insulin receptor. pp120/HA4 was the first member of this family to be identified as a substrate for the insulin receptor (112–116). Based on the sequence flanking the tyrosine phosphorylation site in pp120/HA4, Najjar et al. (117) predicted that the protein would bind to the SH2 domain of SH2-containing phosphotyrosine phosphatases. Subsequently, two other laboratories identified two homologous glycoproteins (SHP substrate-1 [118] and signal-regulatory protein [SIRP] [119]) that were phosphorylated by the insulin receptor and other tyrosine kinases. Furthermore, the phosphorylated proteins did indeed bind to SHP-1 and SHP-2, and served as substrates for these two phosphotyrosine phosphatases. Moreover, SIRP was demonstrated to exert an inhibitory effect on signaling through RTKs.

Subcellular Compartmentalization of Signaling Complexes

Signal specificity may also be determined by localization of signaling complexes to particular subcellular compartments. For example, in adipose cells, there is evidence that insulin stimulation results in the localization of IRS-1/PI3K complexes to GLUT4-containing vesicles (120). The subcellular targeting of PI3K by insulin may help explain why activation of PI3K by insulin results in translocation of GLUT4 but similar activation of PI3K by PDGF does not (73,90). The fact that PDGF stimulation of adipose cells overexpressing PDGF receptors results in translocation of GLUT4 is consistent with the idea that overexpression of proteins may lead to aberrant localization of signaling molecules in compartments where they would normally be excluded (73).

Another subcellular compartment that may contribute importantly to organizing microdomains of signaling complexes are caveolae (small invaginations in the plasma membrane that contain scaffold-like proteins such as caveolins) (121,122). Caveolae are quite abundant in terminally differentiated cell types such as muscle, endothelial, and adipose cells. Furthermore, growth factor receptors such as PDGF and EGF as well as other signaling proteins such as Ras, MAPK, phosphoinositides, G-proteins, calmodulin, and nitric oxide synthase have all been localized to caveolae (some of these interact directly with caveolin) (123–126). Recently it was shown that all the necessary factors for PDGF-stimulated MAP kinase activation (including the PDGF receptor, Ras, Raf1, Mek1, and Erk2) are localized and functionally active in caveolae (123). Interestingly, in 3T3-L1 cells, insulin stimulates the phosphorylation of caveolin only when the cells are differentiated into adipocytes, but not in the fibroblast form (127). Furthermore, in endothelial cells, the interaction of caveolin with nitric oxide synthase is modulated by tyrosine phosphorylation (128,129). Therefore, it is conceivable that some of the specificity in insulin signaling is determined by the organization of signaling complexes in caveolae or other similar subcellular compartments.

Tissue-Specific Expression of Key Effectors

Specific biological responses to insulin may also be determined, in part, by tissue-specific expression of signaling and effector molecules that are necessary for particular actions of insulin. For example, in the case of insulin-stimulated glucose transport, GLUT4 is the major insulin-responsive glucose transporter that is recruited to the cell surface in response to insulin. Since GLUT4 is predominantly expressed in skeletal muscle and adipose tissue, the effect of insulin to increase glucose transport occurs mostly in these tissues. However, transfecting other cell types (e.g., fibroblasts) with GLUT4 and insulin receptors is not sufficient to make cells as responsive to insulin with respect to glucose transport as classical insulin target cells. Thus, there are presumably additional tissue-specific signaling elements important for insulin-stimulated glucose transport besides the insulin receptor and GLUT4.

Another example of the importance of tissue-specific expression of key effectors is demonstrated by the recent finding that caveolin is tyrosine phosphorylated in response to insulin stimulation only in differentiated 3T3-L1 adipocytes, not in undifferentiated 3T3-L1 fibroblasts (127). The phosphorylation of caveolin can be mediated by the kinase fyn, which is thought to be activated by the binding of phosphorylated *c-cbl* in response to insulin stimulation. Interestingly, although the insulin receptor, *c-cbl*, fyn,

and caveolin are all expressed in both 3T3-L1 fibroblasts and adipocytes, insulin stimulation results in phosphorylation of *c-cbl* only in the differentiated 3T3-L1 adipocyte (130). This implies that the kinase responsible for phosphorylation of *c-cbl* in response to insulin (or some other upstream component) is expressed only in the adipocyte, not the fibroblast form of 3T3-L1 cells, and may explain why caveolin is phosphorylated in response to insulin only in adipocytes.

The existence of multiple isoforms of key signaling molecules may also be important for signal specificity. For example, PI3K is essential for insulin-stimulated glucose transport. However, multiple isoforms and splice variants of both the regulatory p85 and catalytic p110 subunits of PI3K that have differential responses to insulin have been discovered (131–137). Each of these isoforms may generate a distinct pattern of lipid products that have specific roles in signaling. The lipid products of PI3K are known to bind to PH domains of downstream effectors, resulting in activation or regulation of these PH domain-containing molecules. Recently, different lipid products of PI3K were shown to have differential binding affinities for particular PH domains from various signaling molecules (138). Thus, the combination of different isoforms of regulatory and catalytic subunits of PI3K in conjunction with tissue-specific expression and localization to subcellular compartments may result in the generation of a particular profile of lipid products that interact in specific ways with downstream effectors that determines the biological response to insulin stimulation.

Feedback Regulation

The function of end products to dampen signals from one pathway while amplifying signals from others is a common mechanism used in the regulation of enzymatic pathways. It is possible that specificity in RTK signal transduction is also determined, in part, by positive or negative feedback. In the case of insulin signaling, it was recently shown that GSK-3 (a downstream metabolic effector of insulin inactivated by Akt) can phosphorylate IRS-1 on serine/threonine residues and inhibit insulin RTK activity (139). Similarly, PI3K (downstream from IRS-1) has serine/threonine kinase activity in addition to its lipid kinase activity and phosphorylates IRS-1 on serine residues, which may result in modulation of IRS-1 function (140). In addition, there is evidence that PI3K has functional interactions both upstream and downstream from Ras, suggesting another feedback loop that may be involved with insulin signaling (141,142).

Modulation of Signal Frequency and Amplitude

Cellular signals generated by changes in ion fluxes or membrane potential often encode information in the modulation of the signal frequency and amplitude. It is conceivable that the dynamics of signaling by RTKs also encode specific information by modulation of the frequency and amplitude of various phosphorylation cascades. For example, it was recently shown that the time course for association between PI3K and IRS-3 in rat adipose cells in response to insulin stimulation is faster than for IRS-1 (87). Furthermore, in the same study, the amount of PI3K associated with IRS-3 in response to insulin stimulation was also greater than for IRS-1. This difference in the time course and amplitude of PI3K activation may help distinguish signals that are mediated by IRS-1 from those by IRS-3 and ultimately result in different biological effects.

SUMMARY

The molecular mechanisms of insulin action follow a general paradigm for RTK signal transduction. As a result, significant progress has been made in recent years to elucidate the insulin signaling pathways involved with the promotion of glucose uptake and metabolism, one of the most distinctive and important biological actions of insulin. A fundamental challenge for future investigations is to understand how specific biological actions of insulin are determined using signaling molecules that are common to signaling pathways used by many other growth factors and cytokines. Convergence and divergence of multiple branching pathways, subcellular compartmentalization, tissue-specific expression of key effectors, and modulation of signal frequency and amplitude are among the potential mechanisms underlying specificity in insulin signaling.

REFERENCES

1. Ullrich A, Bell JR, Chen EY, Herrera R, Petruzzelli LM, Dull TJ, Gray A, Coussens L, Liao YC, Tsubokawa M, Mason A, Seepurg PH, Grunfeld C, Rosen OM, Ramachandran J. Human insulin receptor and its relationship to the tyrosine kinase family of oncogenes. *Nature* 1985; 313:756–761.
2. Ebina Y, Ellis L, Jamagin K, Edery M, Graf L, Clauser E, Ou JH, Masiarz F, Kan YW, Goldfine ID, Roth RA, Rutter WJ. The human insulin receptor cDNA: the structural basis for hormone-activated transmembrane signalling. *Cell* 1985; 40:747–758.
3. Schlessinger J. Cellular signaling by receptor tyrosine kinases. *Harvey Lect* 1993; 89:105–123.
4. van der Geer P, Hunter T, Lindberg RA. Receptor protein-tyrosine kinases and their signal transduction pathways. *Annu Rev Cell Biol* 1994; 10:251–337.
5. Weiss FU, Daub H, Ullrich A. Novel mechanisms of RTK signal generation. *Curr Opin Genet Dev* 1997; 7:80–86.
6. Heldin CH. Dimerization of cell surface receptors in signal transduction. *Cell* 1995; 80:213–223.
7. Lemmon MA, Bu Z, Ladbury JE, Zhou M, Pinchasi D, Lax I, Engelman DM, Schlessinger J. Two EGF molecules contribute additively to stabilization of the EGFR dimer. *EMBO J* 1997; 16:281–294.
8. Czech MP. The nature and regulation of the insulin receptor: structure and function. *Annu Rev Physiol* 1985; 47:357–381.
9. Gustafson TA, Rutter WJ. The cysteine-rich domains of the insulin and insulin-like growth factor I receptors are primary determinants of hormone binding specificity: evidence from receptor chimeras. *J Biol Chem* 1990; 265:18,663–18,667.
10. Lee J, Pilch PF, Shoelson SE, Scarlata SF. Conformational changes of the insulin receptor upon insulin binding and activation as monitored by fluorescence spectroscopy. *Biochemistry* 1997; 36:2701–2708.
11. Ellis L, Morgan DO, Clauser E, Roth RA, Rutter WJ. A membrane-anchored cytoplasmic domain of the human insulin receptor mediates a constitutively elevated insulin-independent uptake of 2-deoxyglucose. *Mol Endocrinol* 1987; 1:15–24.
12. Shoelson SE, White MF, Kahn CR. Tryptic activation of the insulin receptor: proteolytic truncation of the alpha-subunit releases the beta-subunit from inhibitory control. *J Biol Chem* 1988; 263:4852–4860.
13. Kahn CR, Goldfine AB. Molecular determinants of insulin action. *J Diabetes Complications* 1993; 7:92–105.
14. Hubbard SR, Wei L, Ellis L, Hendrickson WA. Crystal structure of the tyrosine kinase domain of the human insulin receptor. *Nature* 1994; 372:746–754.
15. Hubbard SR. Crystal structure of the activated insulin receptor tyrosine kinase in complex with peptide substrate and ATP analog. *EMBO J* 1997; 16:5572–5581.
16. Songyang Z, Shoelson SE, Chaudhuri M, Gish G, Pawson T, Haser WG, King F, Roberts T, Ratnofsky S, Lechleider RJ, Neel BG, Birge RB, Fajardo JE, Chou MM, Hanafusa H. SH2 domains recognize specific phosphopeptide sequences. *Cell* 1993; 72:767–778.
17. Songyang Z, Shoelson SE, McGlade J, Olivier P, Pawson T, Bustelo XR, Barbacid M, Sabe H, Hanafusa H, Yi T, Ren R, Baltimore D, Ratnofsky S, Feldman RA, Cantley LC. Specific motifs recognized by the SH2 domains of Csk, 3BP2, fps/fes, GRB-2, HCP, SHC, Syk, and Vav. *Mol Cell Biol* 1994; 14:2777–2785.

18. Claesson-Welsh L. Signal transduction by the PDGF receptors. *Prog Growth Factor Res* 1994; 5:37–54.
19. Anderson D, Koch C, Grey L, Ellis C, Moran MF, Pawson T. Binding of SH2 domains of phospholipase C gamma 1, GAP, and Src to activated growth factor receptors. *Science* 1990; 250:979–982.
20. Van Horn DJ, Myers MG Jr, Backer JM. Direct activation of the phosphatidylinositol 3'-kinase by the insulin receptor. *J Biol Chem* 1994; 269:29–32.
21. Levy-Toledano R, Taouis M, Blaettler DH, Gorden P, Taylor SI. Insulin-induced activation of phosphatidyl inositol 3-kinase: demonstration that the p85 subunit binds directly to the COOH terminus of the insulin receptor in intact cells. *J Biol Chem* 1994; 269:31,178–31,182.
22. Staubs PA, Reichart DR, Saltiel AR, Milarski KL, Maegawa H, Berhanu P, Olefsky JM, Seely BL. Localization of the insulin receptor binding sites for the SH2 domain proteins p85, Syp, and GAP. *J Biol Chem* 1994; 269:27, 186–27, 192.
23. Myers MG Jr, White MF. Insulin signal transduction and the IRS proteins. *Annu Rev Pharmacol Toxicol* 1996; 36:615–658.
24. Sun XJ, Wang LM, Zhang Y, Yenush L, Myers MG Jr, Glasheen E, Lane WS, Pierce JH, White MF. Role of IRS-2 in insulin and cytokine signalling. *Nature* 1995; 377:173–177.
25. Lavan BE, Lane WS, Lienhard GE. The 60-kDa phosphotyrosine protein in insulin-treated adipocytes is a new member of the insulin receptor substrate family. *J Biol Chem* 1997; 272:11,439–11,443.
26. Holgado-Madruga M, Emlet DR, Moscatello DK, Godwin AK, Wong AJ. A Grb2-associated docking protein in EGF- and insulin-receptor signalling. *Nature* 1996; 379:560–564.
27. Ricketts WA, Rose DW, Shoelson S, Olefsky JM. Functional roles of the Shc phosphotyrosine binding and Src homology 2 domains in insulin and epidermal growth factor signaling. *J Biol Chem* 1996; 271:26,165–26,169.
28. Sasaoka T, Draznin B, Leitner JW, Langlois WJ, Olefsky JM. Shc is the predominant signaling molecule coupling insulin receptors to activation of guanine nucleotide releasing factor and p21ras-GTP formation. *J Biol Chem* 1994; 269:10,734–10,738.
29. Lavan BE, Fantin VR, Chang ET, Lane WS, Keller SR, Lienhard GE. A novel 160-kDa phosphotyrosine protein in insulin-treated embryonic kidney cells is a new member of the insulin receptor substrate family. *J Biol Chem* 1997; 272:21,403–21,407.
30. He W, Craparo A, Zhu Y, O'Neill TJ, Wang LM, Pierce JH, Gustafson TA. Interaction of insulin receptor substrate-2 (IRS-2) with the insulin and insulin-like growth factor I receptors: evidence for two distinct phosphotyrosine-dependent interaction domains within IRS-2. *J Biol Chem* 1996; 271:11,641–11,645.
31. Sawka-Verhelle D, Baron V, Mothe I, Filloux C, White MF, Van Obberghen E. Tyr624 and Tyr628 in insulin receptor substrate-2 mediate its association with the insulin receptor. *J Biol Chem* 1997; 272:16,414–16,420.
32. Quon MJ, Butte AJ, Taylor SI. Insulin signal transduction pathways. *Trends Endocr Metab* 1994; 5:369–376.
33. Cheatham B, Kahn CR. Insulin action and the insulin signaling network. *Endocr Rev* 1995; 16:117–142.
34. Cohen P, Alessi DR, Cross DA. PDK1, one of the missing links in insulin signal transduction? *FEBS Lett* 1997; 410:3–10.
35. Alessi DR, James SR, Downes CP, Holmes AB, Gaffney PR, Reese CB, Cohen P. Characterization of a 3-phosphoinositide-dependent protein kinase which phosphorylates and activates protein kinase Balph. *Curr Biol* 1997; 7:261–269.
36. Cross DA, Watt PW, Shaw M, van der Kaay J, Downes CP, Holder JC, Cohen P. Insulin activates protein kinase B, inhibits glycogen synthase kinase-3 and activated glycogen synthase by rapamycin-insensitive pathways in skeletal muscle and adipose tissue. *FEBS Lett* 1997; 406:211–215.
37. Walton KM, Dixon JE. Protein tyrosine phosphatases. *Annu Rev Biochem* 1993; 62:101–120.
38. Brady-Kalnay SM, Tonks NK. Protein tyrosine phosphatases as adhesion receptors. *Curr Opin Cell Biol* 1995; 7:650–657.
39. Lammers R, Bossenmaier B, Cool DE, Tonks NK, Schlessinger J, Fischer EH, Ullrich A. Differential activities of protein tyrosine phosphatases in intact cells. *J Biol Chem* 1993; 268:22,456–22,462.
40. Goldstein BJ. Regulation of insulin receptor signaling by protein-tyrosine dephosphorylation. *Receptor* 1993; 3:1–15.
41. Chen H, Wertheimer SJ, Lin CH, Katz SL, Amrein KE, Burn P, Quon MJ. Protein-tyrosine phosphatase

- tases PTP1B and Syp are modulators of insulin-stimulated translocation of GLUT4 in transfected rat adipose cells. *J Biol Chem* 1997; 272:8026–8031.
42. Moller NP, Moller KB, Lammers R, Kharitononkov A, Hoppe E, Wiberg FC, Sures I, Ullrich A. Selective down-regulation of the insulin receptor signal by protein-tyrosine phosphatases alpha and epsilon. *J Biol Chem* 1995; 270:23,126–23,131.
 43. Ahmad F, Goldstein BJ. Functional association between the insulin receptor and the transmembrane protein-tyrosine phosphatase LAR in intact cells. *J Biol Chem* 1997; 272:448–457.
 44. Ahmad F, Considine RV, Goldstein BJ. Increased abundance of the receptor-type protein-tyrosine phosphatase LAR accounts for the elevated insulin receptor dephosphorylating activity in adipose tissue of obese human subjects. *J Clin Invest* 1995; 95:2806–2812.
 45. Ahmad F, Azevedo JL, Cortright R, Dohm GL, Goldstein BJ. Alterations in skeletal muscle protein-tyrosine phosphatase activity and expression in insulin-resistant human obesity and diabetes. *J Clin Invest* 1997; 100:449–458.
 46. Tappia PS, Sharma RP, Sale GJ. Dephosphorylation of autophosphorylated insulin and epidermal-growth-factor receptors by two major subtypes of protein-tyrosine-phosphatase from human placenta. *Biochem J* 1991; 278:69–74.
 47. Hashimoto N, Zhang WR, Goldstein BJ. Insulin receptor and epidermal growth factor receptor dephosphorylation by three major rat liver protein-tyrosine phosphatases expressed in a recombinant bacterial system. *Biochem J* 1992; 284:569–576.
 48. Tonks NK, Cicirelli MF, Diltz CD, Krebs EG, Fischer EH. Effect of microinjection of a low-Mr human placenta protein tyrosine phosphatase on induction of meiotic cell division in *Xenopus* oocytes. *Mol Cell Biol* 1990; 10:458–463.
 49. Ahmad F, Li PM, Meyerovitch J, Goldstein BJ. Osmotic loading of neutralizing antibodies demonstrates a role for protein-tyrosine phosphatase 1B in negative regulation of the insulin action pathway. *J Biol Chem* 1995; 270:20,503–20,508.
 50. Ide R, Maegawa H, Kikkawa R, Shigeta Y, Kashiwagi A. High glucose condition activates protein tyrosine phosphatases and deactivates insulin receptor function in insulin-sensitive rat 1 fibroblasts. *Biochem Biophys Res Commun* 1994; 201:71–77.
 51. Maegawa H, Ide R, Hasegawa M, Ugi S, Egawa K, Iwanishi M, Kikkawa R, Shigeta Y, Kashiwagi A. Thiazolidine derivatives ameliorate high glucose-induced insulin resistance via the normalization of protein-tyrosine phosphatase activities. *J Biol Chem* 1995; 270:7724–7730.
 52. Kusari J, Kenner KA, Suh KI, Hill DE, Henry RR. Skeletal muscle protein tyrosine phosphatase activity and tyrosine phosphatase 1B protein content are associated with insulin action and resistance. *J Clin Invest* 1994; 93:1156–1162.
 53. Sugimoto S, Wandless TJ, Shoelson SE, Neel BG, Walsh CT. Activation of the SH2-containing protein tyrosine phosphatase, SH-PTP2, by phosphotyrosine-containing peptides derived from insulin receptor substrate-1. *J Biol Chem* 1994; 269:13,614–13,622.
 54. Ugi S, Maegawa H, Olefsky JM, Shigeta Y, Kashiwagi A. Src homology 2 domains of protein tyrosine phosphatase are associated in vitro with both the insulin receptor and insulin receptor substrate-1 via different phosphotyrosine motifs. *FEBS Lett* 1994; 340:216–220.
 55. Yamauchi K, Milarski KL, Saltiel AR, Pessin JE. Protein-tyrosine-phosphatase SHPTP2 is a required positive effector for insulin downstream signaling. *Proc Natl Acad Sci USA* 1995; 92:664–668.
 56. Xiao S, Rose DW, Sasaoka T, Maegawa H, Burke TR Jr, Roller PP, Shoelson SE, Olefsky JM. Syp (SH-PTP2) is a positive mediator of growth factor-stimulated mitogenic signal transduction. *J Biol Chem* 1994; 269:21,244–21,248.
 57. Milarski KL, Saltiel AR. Expression of catalytically inactive Syp phosphatase in 3T3 cells blocks stimulation of mitogen-activated protein kinase by insulin. *J Biol Chem* 1994; 269:21,239–21,243.
 58. Noguchi T, Matozaki T, Horita K, Fujioka Y, Kasuga M. Role of SH-PTP2, a protein-tyrosine phosphatase with Src homology 2 domains, in insulin-stimulated Ras activation. *Mol Cell Biol* 1994; 14:6674–6682.
 59. Olson AL, Pessin JE. Structure, function, and regulation of the mammalian facilitative glucose transporter gene family. *Annu Rev Nutr* 1996; 16:235–256.
 60. Cushman SW, Wardzala LJ. Potential mechanism of insulin action on glucose transport in the isolated rat adipose cell: apparent translocation of intracellular transport systems to the plasma membrane. *J Biol Chem* 1980; 255:4758–4762.
 61. Suzuki K, Kono T. Evidence that insulin causes translocation of glucose transport activity to the plasma membrane from an intracellular storage site. *Proc Natl Acad Sci USA* 1980; 77:2542–2545.

62. Karnieli E, Zarnowski MJ, Hissin PJ, Simpson IA, Salans LB, Cushman SW. Insulin-stimulated translocation of glucose transport systems in the isolated rat adipose cell: time course, reversal, insulin concentration dependency, and relationship to glucose transport activity. *J Biol Chem* 1981; 256:4772–4777.
63. Satoh S, Nishimura H, Clark AE, Kozka JJ, Vannucci SJ, Simpson IA, Quon MJ, Cushman SW, Holman GD. Use of bismannose photolabel to elucidate insulin-regulated GLUT4 subcellular trafficking kinetics in rat adipose cells: evidence that exocytosis is a critical site of hormone action. *J Biol Chem* 1993; 268:17,820–17,829.
64. Quon MJ. Advances in kinetic analysis of insulin-stimulated GLUT-4 translocation in adipose cells. *Am J Physiol* 1994; 266:E144–E150.
65. Quon MJ, Campfield LA. A mathematical model and computer simulation study of insulin sensitive glucose transporter regulation. *J Theor Biol* 1991; 150:93–107.
66. Sun XJ, Pons S, Wang LM, Zhang Y, Yenush L, Burks D, Myers MG Jr, Glasheen E, Copeland NG, Jenkins NA, Pierce JH, White MF. The IRS-2 gene on murine chromosome 8 encodes a unique signaling adapter for insulin and cytokine action. *Mol Endocrinol* 1997; 11:251–262.
67. Lavan BE, Lienhard GE. The insulin-elicited 60-kDa phosphotyrosine protein in rat adipocytes is associated with phosphatidylinositol 3-kinase. *J Biol Chem* 1993; 268:5921–5928.
68. Kanai F, Ito K, Todaka M, Hayashi H, Kamohara S, Ishii K, Okada T, Hazeki O, Ui M, Ebina Y. Insulin-stimulated GLUT4 translocation is relevant to the phosphorylation of IRS-1 and the activity of PI3-kinase. *Biochem Biophys Res Commun* 1993; 195:762–768.
69. Quon MJ, Zarnowski MJ, Guerre-Millo M, de la Luz Sierra M, Taylor SI, Cushman SW. Transfection of DNA into isolated rat adipose cells by electroporation: evaluation of promoter activity in transfected adipose cells which are highly responsive to insulin after one day in culture. *Biochem Biophys Res Commun* 1993; 194:338–346.
70. Quon MJ, Guerre-Millo M, Zarnowski MJ, Butte AJ, Em M, Cushman SW, Taylor SI. Tyrosine kinase-deficient mutant human insulin receptors (Met1153→Ile) overexpressed in transfected rat adipose cells fail to mediate translocation of epitope-tagged GLUT4. *Proc Natl Acad Sci USA* 1994; 91:5587–5591.
71. Quon MJ, Butte AJ, Zarnowski MJ, Sesti G, Cushman SW, Taylor SI. Insulin receptor substrate 1 mediates the stimulatory effect of insulin on GLUT4 translocation in transfected rat adipose cells. *J Biol Chem* 1994; 269:27,920–27,924.
72. Quon MJ, Chen H, Ing BL, Liu ML, Zarnowski MJ, Yonezawa K, Kasuga M, Cushman SW, Taylor SI. Roles of 1-phosphatidylinositol 3-kinase and ras in regulating translocation of GLUT4 in transfected rat adipose cells. *Mol Cell Biol* 1995; 15:5403–5411.
73. Quon MJ, Chen H, Lin CH, Zhou L, Zarnowski MJ, Klinghoffer R, Kazlauskas A, Cushman SW, Taylor SI. Effects of overexpressing wild-type and mutant PDGF receptors on translocation of GLUT4 in transfected rat adipose cells. *Biochem Biophys Res Commun* 1996; 226:587–594.
74. Zhou L, Chen H, Lin CH, Cong L, McGibbon MA, Sciacchitano S, Lesniak MA, Quon MJ, Taylor SI. Insulin receptor substrate-2 (IRS-2) can mediate the action of insulin to stimulate translocation of GLUT4 to the cell surface in rat adipose cells. *J Biol Chem* 1997; 272:29,829–29,833.
75. Cong L, Chen H, Li Y, Zhou L, McGibbon MA, Taylor SI, Quon MJ. Physiological role for Akt in insulin-stimulated translocation of GLUT4 in transfected rat adipose cells. *Mol Endocrinol* 1997; 11:1881–1890.
76. Araki E, Lipes MA, Patti ME, Bruning JC, Haag B III, Johnson RS, Kahn CR. Alternative pathway of insulin signalling in mice with targeted disruption of the IRS-1 gene. *Nature* 1994; 372:186–190.
77. Tamemoto H, Kadowaki T, Tobe K, Yagi T, Sakura H, Hayakawa T, Terauchi Y, Ueki K, Kaburagi Y, Satoh S, Sekihara H, Yoshioka S, Horikoshi H, Furuta Y, Ikawa Y, Kasuga M, Yazaki Y, Aizawa S. Insulin resistance and growth retardation in mice lacking insulin receptor substrate-1. *Nature* 1994; 372:182–186.
78. Houseknecht KL, Zhu AX, Gnudi L, Hamann A, Zierath JR, Tozzo E, Flier JS, Kahn BB. Overexpression of Ha-ras selectively in adipose tissue of transgenic mice: evidence for enhanced sensitivity to insulin. *J Biol Chem* 1996; 271:11,347–11,355.
79. Tozzo E, Kahn BB, Pilch PF, Kandrор KV. Glut4 is targeted to specific vesicles in adipocytes of transgenic mice overexpressing Glut4 selectively in adipose tissue. *J Biol Chem* 1996; 271:10,490–10,494.
80. Bruning JC, Winnay J, Bonner-Weir S, Taylor SI, Accili D, Kahn CR. Development of a novel

- polygenic model of NIDDM in mice heterozygous for IR and IRS-1 null alleles. *Cell* 1997; 88:561–572.
81. Haruta T, Morris AJ, Rose DW, Nelson JG, Mueckler M, Olefsky JM. Insulin-stimulated GLUT4 translocation is mediated by a divergent intracellular signaling pathway. *J Biol Chem* 1995; 270:27,991–27,994.
 82. Hausdorff SF, Frangioni JV, Birnbaum MJ. Role of p21ras in insulin-stimulated glucose transport in 3T3-L1 adipocytes. *J Biol Chem* 1994; 269:21,391–21,394.
 83. Fingar DC, Birnbaum MJ. A role for Raf-1 in the divergent signaling pathways mediating insulin-stimulated glucose transport. *J Biol Chem* 1994; 269:10,127–10,132.
 84. Kohn AD, Summers SA, Birnbaum MJ, Roth RA. Expression of a constitutively active Akt Ser/Thr kinase in 3T3-L1 adipocytes stimulates glucose uptake and glucose transporter 4 translocation. *J Biol Chem* 1996; 271:31,372–31,378.
 85. Frevert EU, Kahn BB. Differential effects of constitutively active phosphatidylinositol 3-kinase on glucose transport, glycogen synthase activity, and DNA synthesis in 3T3-L1 adipocytes. *Mol Cell Biol* 1997; 17:190–198.
 86. Taylor SI, Cama A, Accili D, Barbetti F, Quon MJ, de la Luz Sierra M, Suzuki Y, Koller E, Levy-Toledano R, Wertheimer E, Moncada VY, Kadowaki H, Kadowaki T. Mutations in the insulin receptor gene. *Endocr Rev* 1992; 13:566–595.
 87. Smith-Hall J, Pons S, Patti ME, Burks DJ, Yenush L, Sun XJ, Kahn CR, White MF. The 60 kDa insulin receptor substrate functions like an IRS protein (pp60IRS3) in adipose cells. *Biochemistry* 1997; 36:8304–8310.
 88. Kaburagi Y, Satoh S, Tamemoto H, Yamamoto-Honda R, Tobe K, Veki K, Yamauchi T, Kono-Sugita E, Sekihara H, Aizawa S, Cushman SW, Akanuma Y, Yazaki Y, Kadowaki T. Role of insulin receptor substrate-1 and pp60 in the regulation of insulin-induced glucose transport and GLUT4 translocation in primary adipocytes. *J Biol Chem* 1997; 272:25,839–25,844.
 89. Tanti JF, Gremeaux T, Grillo S, Calleja V, Klippel A, Williams LT, Van Obberghen E, Le Marchand-Brustel Y. Overexpression of a constitutively active form of phosphatidylinositol 3-kinase is sufficient to promote Glut 4 translocation in adipocytes. *J Biol Chem* 1996; 271:25,227–25,232.
 90. Isakoff SJ, Taha C, Rose E, Marcusohn J, Klip A, Skolnik EY. The inability of phosphatidylinositol 3-kinase activation to stimulate GLUT4 translocation indicates additional signaling pathways are required for insulin-stimulated glucose uptake. *Proc Natl Acad Sci USA* 1995; 92:10,247–10,251.
 91. Klippel A, Kavanaugh WM, Pot D, Williams LT. A specific product of phosphatidylinositol 3-kinase directly activates the protein kinase Akt through its pleckstrin homology domain. *Mol Cell Biol* 1997; 17:338–344.
 92. Franke TF, Kaplan DR, Cantley LC, Toker A. Direct regulation of the Akt proto-oncogene product by phosphatidylinositol-3,4-bisphosphate. *Science* 1997; 275:665–668.
 93. Bandyopadhyay G, Standaert ML, Zhao L, Yu B, Avignon A, Galloway L, Karnam P, Moscat J, Farese RV. Activation of protein kinase C (alpha, beta, and zeta) by insulin in 3T3/L1 cells: transfection studies suggest a role for PKC-zeta in glucose transport. *J Biol Chem* 1997; 272:2551–2558.
 94. Rothman JE, Wieland FT. Protein sorting by transport vesicles. *Science* 1996; 272:227–234.
 95. Rea S, James DE. Moving GLUT4: the biogenesis and trafficking of GLUT4 storage vesicles. *Diabetes* 1997; 46:1667–1677.
 96. Cain CC, Trimble WS, Lienhard GE. Members of the VAMP family of synaptic vesicle proteins are components of glucose transporter-containing vesicles from rat adipocytes. *J Biol Chem* 1992; 267:11,681–11,684.
 97. Martin S, Tellam J, Livingstone C, Slot JW, Gould GW, James DE. The glucose transporter (GLUT-4) and vesicle-associated membrane protein-2 (VAMP-2) are segregated from recycling endosomes in insulin-sensitive cells. *J Cell Biol* 1996; 134:625–635.
 98. Olson AL, Knight JB, Pessin JE. Syntaxin 4, VAMP2, and/or VAMP3/cellubrevin are functional target membrane and vesicle SNAP receptors for insulin-stimulated GLUT4 translocation in adipocytes. *Mol Cell Biol* 1997; 17:2425–2435.
 99. Volchuk A, Wang Q, Ewart HS, Liu Z, He L, Bennett MK, Klip A. Syntaxin 4 in 3T3-L1 adipocytes: regulation by insulin and participation in insulin-dependent glucose transport. *Mol Biol Cell* 1996; 7:1075–1082.
 100. Tellam JT, Macaulay SL, McIntosh S, Hewish DR, Ward CE, James DE. Characterization of Munc-

- 18c and syntaxin-4 in 3T3-L1 adipocytes: putative role in insulin-dependent movement of GLUT-4. *J Biol Chem* 1997; 272:6179–6186.
101. Blakesley VA, Scrimgeour A, Esposito D, Le Roith D. Signaling via the insulin-like growth factor-I receptor: does it differ from insulin receptor signaling? *Cytokine Growth Factor Rev* 1996; 7:153–159.
102. Zeng G, Quon MJ. Insulin-stimulated production of nitric oxide is inhibited by wortmannin: direct measurement in vascular endothelial cells. *J Clin Invest* 1996; 98:894–898.
103. Hansen BF, Danielsen GM, Drejer K, Sorensen AR, Wiberg FC, Klein HH, Lundemose AG. Sustained signalling from the insulin receptor after stimulation with insulin analogues exhibiting increased mitogenic potency. *Biochem J* 1996; 315:271–279.
104. DeMeyts P, Bainco AR, Roth J. Site-site interactions among insulin receptors: characterization of the negative cooperativity. *J Biol Chem* 1976; 251:1877–1888.
105. Ricort JM, Tanti JF, Van Obberghen E, Le Marchand-Brustel Y. Cross-talk between the platelet-derived growth factor and the insulin signaling pathways in 3T3-L1 adipocytes. *J Biol Chem* 1997; 272:19,814–19,818.
106. Velloso LA, Folli F, Sun XJ, White MF, Saad MJ, Kahn CR. Cross-talk between the insulin and angiotensin signaling systems. *Proc Natl Acad Sci USA* 1996; 93:12,490–12,495.
107. Ali MS, Schieffer B, Delafontaine P, Bernstein KE, Ling BN, Marrero MB. Angiotensin II stimulates tyrosine phosphorylation and activation of insulin receptor substrate 1 and protein-tyrosine phosphatase 1D in vascular smooth muscle cells. *J Biol Chem* 1997; 272:12,373–12,379.
108. Folli F, Kahn CR, Hansen H, Bouchie JL, Feener EP. Angiotensin II inhibits insulin signaling in aortic smooth muscle cells at multiple levels: a potential role for serine phosphorylation in insulin/angiotensin II crosstalk. *J Clin Invest* 1997; 100:2158–2169.
109. Bruning JC, Winnay J, Cheatham B, Kahn CR. Differential signaling by insulin receptor substrate 1 (IRS-1) and IRS-2 in IRS-1-deficient cells. *Mol Cell Biol* 1997; 17:1513–1521.
110. Eck MJ, Pluskey S, Trub T, Harrison SC, Shoelson SE. Spatial constraints on the recognition of phosphoproteins by the tandem SH2 domains of the phosphatase SH-PTP2. *Nature* 1996; 379:277–280.
111. Pluskey S, Wandless TJ, Walsh CT, Shoelson SE. Potent stimulation of SH-PTP2 phosphatase activity by simultaneous occupancy of both SH2 domains. *J Biol Chem* 1995; 270:2897–2900.
112. Rees-Jones RW, Taylor SI. An endogenous substrate for the insulin receptor-associated tyrosine kinase. *J Biol Chem* 1985; 260:4461–4467.
113. Perrotti N, Accili D, Marcus-Samuels B, Reese-Jones RW, Taylor SI. Insulin stimulates phosphorylation of a 120-kDa glycoprotein substrate (pp120) for the receptor-associated protein kinase in intact H-35 hepatoma cells. *Proc Natl Acad Sci USA* 1987; 84:3137–3140.
114. Margolis RN, Taylor SI, Seminara D, Hubbard AL. Identification of pp120, an endogenous substrate for the hepatocyte insulin receptor tyrosine kinase, as an integral membrane glycoprotein of the bile canalicular domain. *Proc Natl Acad Sci USA* 1988; 85:7256–7259.
115. Margolis RN, Schell MJ, Taylor SI, Hubbard AL. Hepatocyte plasma membrane ECTO-ATPase (pp120/HA4) is a substrate for tyrosine kinase activity of the insulin receptor. *Biochem Biophys Res Commun* 1990; 166:562–566.
116. Najjar SM, Accili D, Philippe N, Jernberg J, Margolis R, Taylor SI. pp120/ecto-Atpase, an endogenous substrate of the insulin receptor tyrosine kinase, is expressed as two variably spliced isoforms. *J Biol Chem* 1993; 268:1201–1206.
117. Najjar SM, Philippe N, Suzuki Y, Ignacio GA, Formisano P, Accili D, Taylor SI. Insulin-stimulated phosphorylation of recombinant pp120/HA4, an endogenous substrate of the insulin receptor tyrosine kinase. *Biochemistry* 1995; 34:9341–9349.
118. Fujioka Y, Matozaki T, Noguchi T, Iwamatsu A, Yamao T, Takahashi N, Tsuda M, Takada T, Kasuga M. A novel membrane glycoprotein, SHPS-1, that binds the SH2-domain-containing protein tyrosine phosphatase SHP-2 in response to mitogens and cell adhesion. *Mol Cell Biol* 1996; 16:6887–6899.
119. Kharitonov A, Chen Z, Sures I, Wang H, Schilling J, Ullrich A. A family of proteins that inhibit signalling through tyrosine kinase receptors. *Nature* 1997; 386:181–186.
120. Heller-Harrison RA, Morin M, Guilherme A, Czech MP. Insulin-mediated targeting of phosphatidylinositol 3-kinase to GLUT4-containing vesicles. *J Biol Chem* 1996; 271:10,200–10,204.
121. Parton RG. Caveolae and caveolins. *Curr Opin Cell Biol* 1996; 8:542–548.
122. Faux MC, Scott JD. Molecular glue: kinase anchoring and scaffold proteins. *Cell* 1996; 85:9–12.

123. Liu P, Ying Y-S, Anderson RGW. Platelet-derived growth factor activates mitogen-activated protein kinase in isolated caveolae. *Proc Natl Acad Sci USA* 1997; 94:13,666–13,670.
124. Couet J, Sargiacomo M, Lisanti MP. Interaction of a receptor tyrosine kinase, EGF-R, with caveolins: caveolin binding negatively regulates tyrosine and serine/threonine kinase activities. *J Biol Chem* 1997; 272:30,429–30,438.
125. Garcia-Cardena G, Martasek P, Masters BS, Skidd PM, Couet J, Li S, Lisanti MP, Sessa WC. Dissecting the interaction between nitric oxide synthase (NOS) and caveolin: functional significance of the nos caveolin binding domain in vivo. *J Biol Chem* 1997; 272:25,437–25,440.
126. Couet J, Li SW, Okamoto T, Sherer PE, Lisanti MP. *Trends Cardiovasc Med* 1997; 7:103–110.
127. Mastick CC, Saltiel AR. Insulin-stimulated tyrosine phosphorylation of caveolin is specific for the differentiated adipocyte phenotype in 3T3-L1 cells. *J Biol Chem* 1997; 272:20,706–20,714.
128. Garcia-Cardena G, Fan R, Stern DF, Liu J, Sessa WC. Endothelial nitric oxide synthase is regulated by tyrosine phosphorylation and interacts with caveolin-1. *J Biol Chem* 1996; 271:27,237–27,240.
129. Venema VJ, Zou R, Ju H, Marrero MB, Venema RC. Caveolin-1 detergent solubility and association with endothelial nitric oxide synthase is modulated by tyrosine phosphorylation. *Biochem Biophys Res Commun* 1997; 236:155–161.
130. Ribon V, Saltiel AR. Insulin stimulates tyrosine phosphorylation of the proto-oncogene product of c-Cbl in 3T3-L1 adipocytes. *Biochem J* 1997; 324:839–845.
131. Ho LK, Liu D, Rozycka M, Brown RA, Fry MJ. Identification of four novel human phosphoinositide 3-kinases defines a multi-isoform subfamily. *Biochem Biophys Res Commun* 1997; 235:130–137.
132. Brown RA, Ho LK, Weber-Hall SJ, Shipley JM, Fry MJ. Identification and cDNA cloning of a novel mammalian C2 domain-containing phosphoinositide 3-kinase, HsC2-PI3K. *Biochem Biophys Res Commun* 1997; 233:537–544.
133. Inukai K, Funaki M, Ogihara T, Katagiri H, Kanda A, Anai M, Fukushima Y, Hosaka T, Suzuki M, Shin BC, Takata K, Yazaki Y, Kikuchi M, Oka Y, Asano T. p85alpha gene generates three isoforms of regulatory subunit for phosphatidylinositol 3-kinase (PI 3-Kinase), p50alpha, p55alpha, and p85alpha, with different PI 3-kinase activity elevating responses to insulin. *J Biol Chem* 1997; 272:7873–7882.
134. Pons S, Asano T, Glasheen E, Miralpeix M, Zhang Y, Fisher TL, Myers MG Jr, Sun XJ, White MF. The structure and function of p55PIK reveal a new regulatory subunit for phosphatidylinositol 3-kinase. *Mol Cell Biol* 1995; 15:4453–4465.
135. Fruman DA, Cantley LC, Carpenter CL. Structural organization and alternative splicing of the murine phosphoinositide 3-kinase p85 alpha gene. *Genomics* 1996; 37:113–121.
136. Otsu M, Hiles I, Gout I, Fry MJ, Ruiz-Larrea F, Panayotou G, Thompson A, Dhand R, Hsuan J, Totty N, Smith AD, Morgan SJ, Courtneidge SA, Parker PJ, Waterfield MD. Characterization of two 85 kd proteins that associate with receptor tyrosine kinases, middle-T/pp60c-src complexes, and PI3-kinase. *Cell* 1991; 65:91–104.
137. Escobedo JA, Navankasattusas S, Kavanaugh WM, Milfay D, Fried VA, Williams LT. cDNA cloning of a novel 85 kd protein that has SH2 domains and regulates binding of PI3-kinase to the PDGF beta-receptor. *Cell* 1991; 65:75–82.
138. Rameh LE, Arvidsson A, Carraway KL III, Couvillon AD, Rathbun G, Crompton A, VanRenterghem B, Czech MP, Ravichandran KS, Burakoff SJ, Wang DS, Chen CS, Cantley LC. A comparative analysis of the phosphoinositide binding specificity of pleckstrin homology domains. *J Biol Chem* 1997; 272:22,059–22,066.
139. Eldar-Finkelman H, Krebs EG. Phosphorylation of insulin receptor substrate 1 by glycogen synthase kinase 3 impairs insulin action. *Proc Natl Acad Sci USA* 1997; 94:9660–9664.
140. Lam K, Carpenter CL, Ruderman NB, Friel JC, Kelly KL. The phosphatidylinositol 3-kinase serine kinase phosphorylates IRS-1: stimulation by insulin and inhibition by wortmannin. *J Biol Chem* 1994; 269:20,648–20,652.
141. Yamauchi K, Holt K, Pessin JE. Phosphatidylinositol 3-kinase functions upstream of Ras and Raf in mediating insulin stimulation of c-fos transcription. *J Biol Chem* 1993; 268:14,597–14,600.
142. Rodriguez-Viciana P, Warne PH, Vanhaesebroeck B, Waterfield MD, Downward J. Activation of phosphoinositide 3-kinase by interaction with Ras and by point mutation. *EMBO J* 1996; 15:2442–2451.
143. Zhou L, Chen H, Xu P, Cong LN, Sciacchitano S, Li Y, Graham D, Jacobs AR, Taylor SI, Quon MJ. Action of insulin receptor substrate-3 (IRS-3) and IRS-4 to stimulate translocation of GLUT4 in rat adipose cells. *Mol Endo* 1999; 13:505–514.

To date, no AF-1 specific coactivator has been isolated. This will clearly be of great interest, because partial agonists of estrogen and progesterone are believed to exert their actions through this domain. SRC-1 has been reported to interact with both the AF-1 and AF-2 domains, and may contribute to the AF-1 effect in at least some cases (94). Thus, there may be coactivator or modulator proteins that interact with AF-2, AF-1, or both domains. A novel hinge domain-binding coactivator, L7/SPA, has been isolated from HeLa cells, and increased the partial agonist activity of TAM-bound ER and RU486-occupied PR (76).

In general, unliganded ER does not bind to corepressors such as silencing mediator of retinoid and thyroid hormone receptors (SMRT) and nuclear receptor corepressor (NCoR), which bind to the hinge region of nuclear receptors, such as the thyroid hormone receptors and RARs, and prevent binding of the LBD regions to coactivators (41). In these receptors, the corepressor proteins invoke a receptor conformation that actively represses transcription, owing partially to histone acetylase activity of the coactivator proteins. Specific conformations of ER, resulting from binding to receptor antagonists, may result in corepressor recruitment to the liganded receptor complexes. For example, in HepG2 liver cells, in which tamoxifen is a partial agonist, exogenous SRC-1 enhanced E and TAM-stimulated transcription, whereas overexpression of the corepressor SMRT strongly reduced basal and TAM-mediated transcription with no effects on E activity (86). Similarly, PR bound to antiprogestins of the partial agonist class binds more effectively to corepressors N-CoR and SMRT than does PR bound to other ligands (76,95), and this association can be suppressed by treatment of cells with cAMP (95). Unliganded PR may bind to corepressors, and additional corepressors with more complicated or specific receptor requirements may exist. For example, human ER LBD bound to antiestrogens such as tamoxifen, but not bound to E, associates with at least one nuclear protein capable of acting as a corepressor (96). Such molecules would not be isolated using only ligand-bound receptors as bait in typical two-hybrid or other protein interaction assays. Additional studies will undoubtedly focus on the types of accessory proteins bound to specific receptors with various ligands, as well as modifications of those proteins by intracellular signaling cascades.

SUMMARY

Overall, several factors including the character of the ligand, the steroid receptor isoform expressed in a specific cell type, and intracellular signaling pathways activated in a given cell or tissue may all be important in determining the character of partial steroid antagonists. At least some of these responses are directly related to the complement of coactivators and corepressors associated with ligand-bound receptor within a given context. As we have discussed, the levels of individual coactivators and corepressors may be modulated physiologically, and it is likely that posttranslational modifications will also occur in response to signaling cascades by growth factors and other bioactive peptides. Individual ligand binding to specific receptor isoforms confers distinct conformational changes and contours to the receptors, capable of interacting with the cellular accessory proteins. Based on both the identity and levels of coactivators and corepressors, the resulting receptor protein complex will have either a stimulatory or suppressive conformation and a resulting effect on model gene transcription. An additional layer of diversity will then be provided by the specific ERE or responsive promoter region

in the cellular target genes, since the receptor conformation may be altered as it binds to different DNA sequences, or contacts different proteins at nearby promoter regions. These interactions can alter the essential character of a given ligand, from antagonist to agonist or the reverse. Current and future studies will be focused on the essential mechanisms underlying such diversity and specificity, and how these processes can be regulated or manipulated for a given positive biological outcome.

REFERENCES

1. Mangelsdorf DJ, Thummel C, Beato M, Herrlich P, Schutz G, Umesono K, et al. The nuclear receptor superfamily: the second decade. *Cell* 1995; 83:835–839.
2. Green S, Chambon P. The oestrogen receptor: from perception to mechanism. In: Parker M, ed. *Nuclear Hormone Receptors*. Academic, New York, pp. 15–18.
3. MacGregor JJ, Jordan VC. Basic guide to the mechanisms of antiestrogen action. *Pharm Rev* 1998; 50:151–196.
4. Bourguet W, Ruff M, Chambon P, Gronemeyer H, Moras D. Crystal structure of the ligand-binding domain of the human receptor RXT- α . *Nature* 1995; 375:377–382.
5. Renaud J-P, Rochel N, Ruff M, Vivat V, Chambon P, Gronemeyer H, Moras D. Crystal structure of the RAR gamma ligand binding domain bound to all-trans retinoic acid. *Nature* 1995; 378:681–689.
6. Tanenbaum DM, Wang Y, Williams SP, Sigler PB. Crystallographic comparison of the estrogen and progesterone receptor's ligand binding domains. *Proc Natl Acad Sci USA* 1998; 95:5998–6003.
7. Tora L, White J, Brou C, Tasset D, Webster N, Scheer E, Chambon P. The human estrogen receptor has two independent nonacidic transcriptional activation functions. *Cell* 1989; 59:477–487.
8. Berry M, Metzger D, Chambon P. Role of the two activating domains of the oestrogen receptor in the cell-type and promoter-context dependent agonistic activity of the anti-oestrogen 4-hydroxytamoxifen. *EMBO J* 1990; 9:2811–2818.
9. Feng W, Ribiero RC, Wagner RL, Nguyen H, Apriletti JW, Fletterick RJ, et al. Hormone-dependent coactivator binding to a hydrophobic cleft on nuclear receptors. *Science* 1998; 280:1747–1749.
10. Daneilian PS, White R, Hoare SA, Fawell SE, Parker MG. Identification of residues in the estrogen receptor that confer differential sensitivity to estrogen and hydroxytamoxifen. *Mol Endocrinol* 1993; 7:232–240.
11. Beekman JM, Allan GF, Tsai SY, Tsai M-J, O'Malley BW. Transcriptional activation by the estrogen receptor requires a conformational change in the ligand binding domain. *Mol Endocrinol* 1993; 7:1266–1274.
12. Brzozowski AM, Pike AC, Dauter Z, Hubbard RE, Bonn T, Engstrom O, et al. Molecular basis of agonism and antagonism in the oestrogen receptor. *Nature* 1997; 389:753–758.
13. Williams SP, Sigler PB. Atomic structure of progesterone complexed with its receptor. *Nature* 1998; 393:392–396.
14. Shiau AK, Barstad D, Loria PM, Cheng L, Kushmer PJ, Agard DA, Greene GL. The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen. *Cell* 1998; 95:927–937.
15. Montano MM, Müller V, Trobaugh A, Katzenellenbogen BS. The carboxy-terminal F domain of the human estrogen receptor: role in the transcriptional activity of the receptor and the effectiveness of antiestrogens as estrogen antagonists. *Mol Endocrinol* 1995; 9:814–825.
16. Koehorst SG, Cox JJ, Donker GH, daSilva SL, Burbach JPH, Thijssen JHH, Blankenstein MA. Functional analysis of an alternatively spliced estrogen receptor lacking exon 4 isolated from MCF-7 breast cancer cells and meningioma tissue. *Mol Cell Endocrinol* 1994; 101:237–245.
17. Koike S, Sakai M, Muramatsu M. Molecular cloning and characterization of rat estrogen receptor cDNA. *Nucleic Acids Res* 1987; 15:2499–2513.
18. Shupnik MA, Gordon M, Chin WW. Tissue-specific regulation of the rat estrogen receptor mRNAs. *Mol Endocrinol* 1989; 3:660–665.
19. Friend KE, Ang LW, Shupnik MA. Estrogen regulates the expression of several different estrogen receptor mRNA isoforms in rat pituitary. *Proc Natl Acad Sci USA* 1995; 92:4367–4371.
20. Kuiper GGJM, Enmark E, Peltö-Huikko M, Nilsson S, Gustafsson J-Å. Cloning of a novel estrogen receptor expressed in rat prostate and ovary. *Proc Natl Acad Sci USA* 1996; 93:5925–5930.

21. Mosselman S, Polman J, Dijkema R. ER β : identification and characterization of a novel human estrogen receptor. *FEBS Lett* 1996; 392:49–53.
22. Kuiper GG, Carlsson B, Grandien K, Enmark E, Haggblad J, Nilsson S, Gustafsson JA. Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors alpha and beta. *Endocrinology* 1997; 138:863–870.
23. Shupnik MA, Pitt LK, Soh AY, Anderson A, Lopes MB, Laws ER, Jr. Selective expression of estrogen receptor alpha and beta isoforms in human pituitary tumors. *J Clin Endocrinol Metab* 1998; 83:3965–3972.
24. Byers M, Kuiper GGJM, Gustafsson J-Å, Park-Sarge O-K. Estrogen receptor- β mRNA expression in rat ovary: down regulation by gonadotropins. *Mol Endocrinol* 1997; 11:172–182.
25. Korach KS, Couse JF, Curtis SW, Washburn TF, Lindzey J, Kimbro KS, et al. Estrogen receptor gene disruption: molecular characterization and experimental and clinical phenotypes. *Recent Prog Horm Res* 1996; 51:159–186.
26. Kregge JH, Hodgin JB, Couse JF, Enmark E, Warner M, Mahler JF, et al. Generation and reproductive phenotypes of mice lacking estrogen receptor β . *Proc Natl Acad Sci USA* 1998; 95:15,677–15,682.
27. Smith ER, Boyd J, Frank GR, Takahashi H, Cohen RM, Specker B, et al. Estrogen resistance caused by a mutation in the estrogen receptor gene in a man. *N Engl J Med* 1995; 331:1051–1061.
28. Kuiper GGJM, Lemmen JG, Carlsson B, et al. Interaction of estrogenic chemicals and phytoestrogens with estrogen receptor β . *Endocrinology* 1998; 139:4252–4263.
29. Petersen DN, Tkalecic GT, Koza-Taylor PH, Turi TG, Brown TA. Identification of estrogen receptor β_2 , a functional variant of estrogen receptor β expressed in normal rat tissues. *Endocrinology* 1998; 139:1082–1092.
30. Sun J, Meyers MJ, Fink BE, Rajendran R, Katzenellenbogen JA, Katzenellenbogen BS. Novel ligands that function as selective estrogens and antiestrogens for estrogen receptor- α and estrogen receptor- β . *Endocrinology* 1999; 140:800–804.
31. Montano MM, Ekena K, Kreuger KD, Keller AL, Katzenellenbogen BS. Human estrogen receptor ligand activity inversion mutants: receptors that interpret antiestrogens as estrogens and estrogens as antiestrogens and discriminate among different antiestrogens. *Mol Endocrinol* 1996; 10:230–242.
32. Pettersson K, Grandien K, Kuiper GGJM, Gustafsson J-Å. Mouse estrogen receptor beta forms estrogen response element-binding heterodimers with estrogen receptor α . *Mol Endocrinol* 1997; 11:1486–1496.
33. Giangrande PH, Pollio G, McDonnell DP. Mapping and characterization of the functional domains responsible for the differential activity of the A and B isoforms of the human progesterone receptor. *J Biol Chem* 1997; 272:32,889–32,900.
34. Katzenellenbogen BS. Estrogen receptors: bioactivities and interactions with cell signaling pathways. *Biol Reprod* 1996; 54:287–293.
35. Kumar NS, Richer J, Owen G, Litman E, Horwitz KB, Leslie KK. Selective down-regulation of progesterone receptor isoform B in poorly differentiated human endometrial cancer cells: implications of unopposed estrogen action. *Cancer Res* 1998; 58:1860–1865.
36. Mangal RK, Wiechle RD, Poindexter AN, Weigel NL. Differential expression of uterine progesterone receptor forms A and B during the menstrual cycle. *J Steroid Biochem Mol Biol* 1997; 63:195–202.
37. Lydon JP, DeMayo FJ, Funk CR, Mani SK, Hughes AR, Montgomery CA, et al. Mice lacking progesterone receptor exhibit pleiotropic reproductive abnormalities. *Genes Dev* 1995; 9:2266–2278.
38. McDonnell DP, Clemm DL, Hermann T, Goldman ME, Pike JW. Analysis of estrogen receptor function *in vitro* reveals three distinct classes of antiestrogens. *Mol Endocrinol* 1995; 9:659–669.
39. Doesburg P, Kuil CW, Berrevoets CA, Steketee K, Faber PW, Mulder E, et al. Functional *in vivo* interaction between the amino-terminal transactivation domain and the ligand binding domain of the androgen receptor. *Biochemistry* 1997; 36:1052–1064.
40. Gandini O, Kahno H, Curtis S, Korach KS. Two transcription activation functions in the amino terminus of the mouse estrogen receptor that are affected by the carboxy terminus. *Steroids* 1997; 62:508–515.
41. Horwitz KB, Jackson TA, Bain DL, Richer JK, Takimoto GS, Tung L. Nuclear receptor coactivators and corepressors. *Mol Endocrinol* 1996; 10:1167–1177.
42. Oñate S, Tsai SY, Tsai M-J, O'Malley BW. Sequence and characterization of a coactivator for the steroid hormone receptor superfamily. *Science* 1995; 270:1354–1357.
43. Anzick SL, Kononen J, Walker RL, Azorsa DO, Tanner MM, Guan XY, et al. AIB1, a steroid receptor coactivator amplified in breast and ovarian cancer. *Science* 1997; 277:965–968.
44. Danielian PS, White R, Lees JA, Parker MG. Identification of a conserved region required for hormone dependent transcriptional activation by steroid hormone receptors. *EMBO J* 1992; 11:1025–1033.

45. Kato S, Endoh H, Masuhiro Y, Kitamoto T, Uchiyama S, Sasaki H, et al. Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase. *Science* 1995; 270:1491–1494.
46. Joel PB, Smith J, Sturgill TW, Fisher TL, Blenis J, Lannigan DA. pp90^{rsk} regulates estrogen receptor-mediated transcription through phosphorylation of Ser-167. *Mol Cell Biol* 1998; 18:1978–1984.
47. Fujimoto N, Katzenellenbogen B. Alteration in the agonist/antagonist balance of antiestrogens by activation of protein kinase A signaling pathways in breast cancer cells: antiestrogen selectivity and promoter dependence. *Mol Endocrinol* 1994; 8:296–304.
48. Smith CL, Conneely OM, O'Malley BW. Modulation of the ligand-independent activation of the human estrogen receptor by hormone and antihormone. *Proc Natl Acad Sci USA* 1993; 90:6120–6124.
49. Sartorius CA, Tung L, Takimoto GS, Horwitz KB. Antagonist-occupied human progesterone receptors bound to DNA are functionally switched to transcriptional agonists by cAMP. *J Biol Chem* 1993; 268:9262–9266.
50. LeGoff P, Montano MM, Shodin DJ, Katzenellenbogen BS. Phosphorylation of the human estrogen receptor: identification of hormone regulated sites and examination of their influence on transcriptional activity. *J Biol Chem* 1994; 269:4458–4466.
51. Bai W, Rowan BG, Allgood VE, O'Malley BW. Differential phosphorylation of chicken progesterone receptor in hormone-dependent and ligand-independent activation. *J Biol Chem* 1997; 272:10,457–10,463.
52. Zhang Y, Beck CA, Poletti A. Phosphorylation of the human progesterone receptor by cyclin-dependent kinase 2 on three sites that are authentic basal phosphorylation sites *in vivo*. *Mol Endocrinol* 1997; 11:823–832.
53. Smith CL. Cross-talk between peptide growth factor and estrogen receptor signaling pathways. *Biol Reprod* 1998; 58:627–632.
54. Sartorius CA, Melville MY, Hovland AR, Tung L, Takimoto GS, Horwitz KB. A third transactivation function (AF3) of human progesterone receptors located in the unique N-terminal segment of the B-isoform. *Mol Endocrinol* 1994; 8:1347–1360.
55. Hovland AR, Powell RL, Takimoto GS, Tung L, Horwitz KB. An N-terminal inhibitory function, IF, suppresses transcription by the A-isoform but not the B-isoform of human progesterone receptors. *J Biol Chem* 1996; 273:5455–5460.
56. Tung L, Mohamed MK, Hoeffler JP, Takimoto GS, Horwitz KB. Antagonist-occupied human progesterone B-receptors activate transcription without binding to progesterone response elements and are dominantly inhibited by A-receptors. *Mol Endocrinol* 1993; 7:1256–1265.
57. Wakeling AE, Dukes M, Bowler J. A potent specific pure antiestrogen with clinical potential. *Cancer Res* 1991; 51:3867–3873.
58. Tremblay A, Tremblay GB, Labrie C, Labrie F, Giguère V. EM-800, a novel antiestrogen, acts as a pure antagonist of the transcriptional functions of estrogen receptors α and β . *Endocrinology* 1998; 139:111–118.
59. Tzukermann MT, Esty A, Santiso-Mere D, Danielian P, Parker MG, Stein RB, et al. Human estrogen receptor transactivated capacity is determined by both cellular and promoter context and mediated by two functionally distinct intramolecular regions. *Mol Endocrinol* 1994; 8:21–30.
60. Tremblay GB, Tremblay A, Labrie F, Giguère V. Dominant activity of activation function 1 (AF-1) and differential stoichiometric requirements for AF-1 and -2 in the estrogen receptor α - β heterodimeric complex. *Mol Cell Biol* 1999; 19:1919–1927.
61. Dauvois S, White R, Parker MG. The antiestrogen ICI 182780 disrupts estrogen receptor nucleocytoplasmic shuttling. *J Cell Sci* 1993; 106:1377–1388.
62. McInerney EM, Weis KE, Sun J, Mosselman S, Katzenellenbogen BS. Transcription activation by the human estrogen receptor subtype β (ER β) studied with ER β and ER α receptor chimeras. *Endocrinology* 1998; 139:4513–4522.
63. Webb P, Lopez GN, Uht RM, Kushner P. Tamoxifen activation of the estrogen receptor/AP-1 pathway: potential origin for the cell-specific estrogen-like effects of antiestrogens. *Mol Endocrinol* 1995; 9:443–456.
64. Paech K, Webb P, Kuiper GGJM, Nilsson S, Gustafsson J-Å, Kushner PJ, Scanlan TS. Differential ligand activation of estrogen receptors ER α and ER β at AP1 sites. *Science* 1997; 277:1508–1510.
65. Barsalou A, Gao W, Anghel SI, Carrière J, Mader S. Estrogen response elements can mediate agonist activity of anti-estrogens in human endometrial Ishikawa cells. *J Biol Chem* 1998; 273:17,138–17,146.
66. Sukovich DA, Mukherjee R, Benfield PA. A novel, cell-type specific mechanism for estrogen receptor-

- mediated gene activation in the absence of an estrogen-responsive element. *Mol Cell Biol* 1994; 14:7134–7143.
67. Blin C, L'Horsset F, Leclerc T, Lambert M, Colnot S, Thomasset M, Perret C. Contrasting effects of tamoxifen and ICI 182 780 on estrogen-induced calbindin-D 9k gene expression in the uterus and in primary culture of myometrial cells. *J Steroid Biochem Mol Biol* 1995; 55:1–7.
 68. Zou A, Marschke KB, Arnold KE, Berger EM, Fitzgerald P, Mais DE, Allegretto EA. Estrogen receptor β activates the human retinoic acid receptor α -1 promoter in response to tamoxifen and other estrogen receptor antagonists, but not in response to estrogen. *Mol Endocrinol* 1999; 13:418–430.
 69. Montano MM, Kraus WL, Katzenellenbogen BS. Identification of a novel transferable cis element in the promoter of an estrogen-responsive gene that modulates sensitivity to hormone and antihormone. *Mol Endocrinol* 1997; 11:330–341.
 70. Montano MM, Jaiswal AK, Katzenellenbogen BS. Transcriptional regulation of the human quinone reductase gene by antiestrogen-liganded estrogen receptor- α and estrogen receptor- β . *J Biol Chem* 1998; 273:25,443–25,449.
 71. Allan GF, Leng X, Tsai SY, Weigel NL, Edwards DP, Tsai MJ, O'Malley BW. Hormone and antihormone induce distinct conformational changes which are central to steroid receptor activation. *J Biol Chem* 1992; 267:19,513–19,520.
 72. Allan GF, Lombardi E, Haynes-Johnson D, Palmer S, Kiddoe M, Kraft P, et al. Induction of a novel conformation in the progesterone receptor by ZK299 involves a defined region of the carboxyl-terminal tail. *Mol Endocrinol* 1996; 10:1206–1213.
 73. Weigel NL, Beck CA, Estes PA, Prendergast P, Altmann M, Christensen K, Edwards DP. Ligands induce conformational changes in the carboxyl-terminus of progesterone receptors which are detected by a site-directed antipeptide monoclonal antibody. *Mol Endocrinol* 1992; 6:1585–1597.
 74. Clemm DL, Macy BL, Santiso-Mere D, McDonnell DP. Definition of the critical cellular components which distinguish between hormone and antihormone activated progesterone receptor. *J Steroid Biochem Mol Biol* 1995; 53:487–495.
 75. Vegeto E, Allan GF, Schrader WT, Tsai MJ, McDonnell DP, O'Malley BW. The mechanism of RU486 antagonism is dependent on the conformation of the carboxy-terminal tail of the human progesterone receptor. *Cell* 1992; 69:703–713.
 76. Jackson TA, Richer JK, Bain DL, Takimoto GS, Tung L, Horwitz KB. The partial agonist activity of antagonist-occupied steroid receptors is controlled by a novel hinge domain-binding coactivator L7/SPA and the corepressors N-CoR or SMRT. *Mol Endocrinol* 1997; 11:693–705.
 77. Edwards DP, Altmann M, DeMarzo A, Zhang Y, Weigel NL, Beck CA. Progesterone receptor and the mechanism of action of progesterone antagonists. *J Steroid Biochem Mol Biol* 1995; 53:449–458.
 78. Wagner BL, Pollio G, Leonhardt S, Wani MC, Lee DY, Imhof MO, et al. 16 Alpha-substituted analogs of the antiprogesterin RU486 induce a unique conformation in the human progesterone receptor resulting in mixed agonist activity. *Proc Natl Acad Sci USA* 1996; 93:8739–8744.
 79. Vegeto E, Shahbaz MM, Wen DX, Goldman ME, O'Malley BW, McDonnell DP. Human progesterone receptor A form is a cell- and promoter-specific repressor of human progesterone receptor B function. *Mol Endocrinol* 1993; 7:1244–1255.
 80. Devin-Leclerc J, Meng X, Dalahaye F, Leclerc P, Baulieu E-E, Catelli M-G. Interaction and dissociation by ligands of estrogen receptor and Hsp90: the antiestrogen RU58668 induces a protein synthesis-dependent clustering of receptor in the cytoplasm. *Mol Endocrinol* 1998; 12:842–854.
 81. Ekena K, Weis KE, Katzenellenbogen JA, Katzenellenbogen BS. Different residues of the human estrogen receptor are involved in the recognition of structurally diverse estrogens and antiestrogens. *J Biol Chem* 1997; 272:5069–5075.
 82. Catherino WH, Wolf DM, Jordan VC. A naturally occurring estrogen receptor mutation results in increased estrogenicity of a tamoxifen analog. *Mol Endocrinol* 1995; 9:1053–1063.
 83. Mahfoudi A, Roulet E, Dauvois S, Parker MG, Wahli W. Specific mutations in the estrogen receptor change the properties of antiestrogens to full agonists. *Proc Natl Acad Sci USA* 1995; 92:4206–4210.
 84. Pakdel F, Katzenellenbogen BS. Human estrogen receptor mutants with altered estrogen and antiestrogen ligand discrimination. *J Biol Chem* 1992; 267:3429–3437.
 85. Hanstein B, Eckner R, DiRenzo J, Halachmi S, Liu H, Searcy B, et al. p300 is a component of an estrogen receptor coactivator complex. *Proc Natl Acad Sci USA* 1996; 93:11,540–11,545.
 86. Smith CL, Nawaz Z, O'Malley BW. Coactivator and corepressor regulation of the agonist/antagonist activity of the mixed antiestrogen, 4-hydroxytamoxifen. *Mol Endocrinol* 1997; 11:657–666.

87. Misiti S, Schomburg L, Yen PM, Chin WW. Expression and hormonal regulation of coactivator and corepressor genes. *Endocrinology* 1998; 139:2493–2500.
88. Yeh S, Chang C. Cloning and characterization of a specific coactivator, ARA70, for the androgen receptor in human prostate cells. *Proc Natl Acad Sci USA* 1996; 93:5517–5521.
89. Xu J, Qiu Y, DeMayo FJ, Tsai SY, Tsai M-J, O'Malley BW. Partial hormone resistance in mice with disruption of the steroid receptor coactivator-1 (SRC-1) gene. *Science* 1998; 279:1922–1925.
90. Treuter E, Albrechtsen T, Johansson L, Leers J, Gustafsson JA. A regulatory role for Rip140 in nuclear receptor activation. *Mol Endocrinol* 1998; 12:864–881.
91. Norris JD, Fan D, Stallcup MR, McDonnell DP. Enhancement of estrogen receptor transcriptional activity by the coactivator GRIP-1 highlights the role of activation function 2 in determining estrogen receptor pharmacology. *J Biol Chem* 1998; 272:6679–6688.
92. Seol W, Heanstein B, Brown M, Moore DD. Inhibition of estrogen receptor action by the orphan receptor SHP (short heterodimer partner). *Mol Endocrinol* 1998; 12:1551–1557.
93. Schreihöfer DA, Resnick EM, Soh AY, Shupnik MA. Transcriptional regulation by a naturally occurring rat estrogen receptor variant, TERP-1. *Mol Endocrinol* 1999; 13:320–329.
94. Oñate SA, Boonyaratanakornkit V, Spencer TE, Tsai SY, Tsai MJ, Edwards DP, O'Malley BW. The steroid receptor coactivator-1 contains multiple receptor interacting and activation domains that cooperatively enhance the activation function 1 (AF1) and AF2 domains of steroid receptors. *J Biol Chem* 1998; 273:12,101–12,108.
95. Wagner BI, Norris JD, Knotts TA, Weigel NL, McDonnell DP. The nuclear corepressors NcoR and SMRT are key regulators of both ligand- and 8-bromo-cyclic AMP-dependent transcriptional activity of the human progesterone receptor. *Mol Cell Biol* 1998; 18:1369–1378.
96. Montano MM, Chang W, Katzenellenbogen BS. An estrogen-selective corepressor: cloning and characterization. The Endocrine Society 80th Annual Meeting. New Orleans, LA, June 24–27, 1998, p. 96.

INDEX

A

- Activin gene structure, 286
- Activin subunits, 182
- Activin β A subunit gene knock-out, 182, 262
- Activin β B subunit gene knock-out, 182, 195
- Activin receptor I gene knock-outs 182, 183
- Activin receptor II gene knock-out 182–184, 197, 262
- Adrenal gland
 - Development, 159
 - Mutations in DAX-1 and gland dysfunction, 156, 157, 159
 - Mutations in SF-1 and gland dysfunction, 156, 157, 159
- Adrenal hypoplasia congenita,
 - Developmental gene knock-outs, 156, 157
 - StAR gene mutations, 250, 253
- Androgens
 - Bioavailability, 374
 - Dihydrotestosterone, 352, 357, 374
 - Testosterone, 352, 357, 359, 373
- Androgen insensitivity, 353–358; *see also* Testicular feminization
 - Androgen receptor mutations, 352–358, 383–386
 - Partial, 354, 358
 - Phenotype, 383
 - Reifenstein syndrome, 353
 - Spinal bulbar muscular atrophy, 386, 387
 - Testicular feminization, 353
- Androgen receptor
 - Coactivators and corepressors, 346–349, 381–382
 - Mutations and phenotypes, 168, 352–358, 383–386
 - Nuclear transport, 91, 92
 - Phosphorylation and ligand-independent activation, 352, 394, 395–398
 - Structure and function, 340, 378–381
 - Structural N-terminal repeats, 341
- Anterior pituitary
 - Development of gene lineages, 46, 47, 170, 171
 - Gene knock-out models with pituitary defects, 177–179, 194
 - Pituitary-specific thyroid hormone receptor, 137, 138
 - Tumors and Ets factors, 53, 54
 - Tumorigenesis models, 229, 230
- Antiandrogens, 350, 351
 - Casodex, 351
 - Flutamide, 350
- Antiestrogens
 - ICI compounds and Type II antagonist action, 413–416
 - Influence on coactivator and corepressor binding, 420–421
 - Receptor isoform selectivity, 410
 - Structural consequences of receptor binding, 412, 417–419
 - Tamoxifen and Type I antagonist action, 412, 414–416
- Antiprogestins
 - Influence on coactivator and corepressor binding, 420, 421
 - RU486 and Type II antagonists, 416
 - Structural consequences of receptor binding, 420, 421
 - ZK98299 and Type I antagonists, 416, 417
- ARA70, 348, 349
- Aromatase
 - Ovarian, 243, 253
 - Testicular, 375

B

- Bone morphogenic proteins in reproduction, 183, 184
- Brain development and thyroid hormones, 121–123
- Breast cancer

- Amplification of AIB1, 112
- Ets transcription factors, 54, 55
- Male, 388, 389
- C**
- cAMP, *see* cyclic adenosine monophosphate (cAMP)
- Cell cycle regulators and DNA repair, 195, 198–203
- Cervical cancer
 - Ets transcription factors, 55
- Coactivators, *see* steroid receptors
- Consensus sequences
 - CREB, 326
 - Ets transcription factor binding sites, 42
 - Pit-1 binding sites, 69
 - SF-1 binding sites, 154
 - Thyroid hormone response elements, 103, 104
 - Steroid receptors, 393
- Corepressors, *see* steroid receptors
- Cyclic adenosine monophosphate (cAMP)-responsive transcription factors, 280–283
- Cyclic AMP response element binding protein (CREB)
 - Activation of protein kinase activity, 326–328
 - Binding to inhibin α -subunit gene promoter, 290–292, 298
 - Expression of variants during spermatogenesis, 330–333
 - Gene knock-out, 328
 - Gene structure and splicing, 282, 327
 - Phosphorylation and gene activation in ovary, 283, 292–294
- Cyclic AMP response element modulatory protein (CREM), *see also* ICER
 - Activator and repressor forms during spermatogenesis, 333
 - Gene knock-out, 328
 - Gene structure and alternative splicing, 282, 327
- Cyclic AMP response element modulatory protein binding protein (CBP)
 - Biological activity, 81, 111, 139–141
 - Interaction with steroid receptor coactivators, 350, 381, 420
 - Mutation in Rubenstein–Taybes syndrome, 111
- Cyclin D2, 260
- Cytochrome P450 side-chain cleavage enzyme
 - Biological activity, 247
 - Cell localization, 246
 - Expression in ovary, 250, 251
 - Expression in placenta, 313
- Cytokines
 - Receptors and signaling, 2–4
 - Gene knock-out models, 185, 186
- D**
- DAX-1 (dosage-sensitive sex-reversal adrenal hypoplasia congenita critical region of the X chromosome 1)
 - Endocrine organ development, 158–160, 172
 - Interactions with SF-1, 161–163
 - Structure, 154
- DAX-1 human mutations and clinical manifestations
 - Adrenal hypoplasia congenita, 156, 157, 159
 - Dosage-sensitive sex-reversal syndrome, 157–160
 - Hypogonadotropic hypogonadism, 156, 157, 159
- Diabetes mellitus, 17, 22
- E**
- Early growth response protein-1 (Egr-1), 170, 171, 262
- Early growth response protein-1 gene knock-out, 244, 263
- Estrogen receptor (ER)
 - ER α gene knock-out model, 187, 188, 197, 410
 - ER α gene knock-out and reproductive dysfunction, 240, 410
 - ER α gene mutation in humans, 410
 - ER β gene knock-out and reproductive function, 410
 - Phosphorylation and ligand-independent activation, 395–399, 411, 412
 - Structure of isoforms, 409

- Tissue distribution of isoforms, 410
- Estrogen-related receptor β gene knock-out and placental abnormalities, 188, 316
- Ets transcription factors
 - DNA binding, 40, 42
 - Gene knockout and infertility, 52
 - Integration of hormonal signaling, 48–51
 - Involvement in carcinogenesis, 52–56
 - Pituitary and hypothalamus, 42–48
 - Structure of family members, 41

F

- Follicle, *see* Ovarian follicle
- Follicle-stimulating hormone (FSH)
 - Activin effects, 182, 183
 - GnRH effects, 226
 - Inhibin effects, 182
 - Steroid effects, 226
 - FSH β gene knock-out, 180, 197, 262
 - FSH β gene promoter, 224
 - FSH β gene regulation, 226
 - FSH β human gene transgenic mice, 225, 226

G

- Gene knock-out (gene inactivation) technology, 172–175
- GHF-1; *see* Pit-1
- Glucocorticoid receptor
 - Interactions with molecular chaperones, 90–92
 - Non-consensus negative gene response elements, 93, 94
 - Nuclear transport 87, 88
 - Nuclear export, 89, 90
 - Phosphorylation, 399
 - Unique genomic sites and protein-protein interactions, 92, 93
- Glucose transport
 - Insulin responsive glucose transporter (GLUT4), 22–28
- Gonadal development, 156–160, 170–172
 - Gene knock-out models and developmental defects, 155–157, 179–187
- Gonadotropes
 - Absence in SF-1 knock-out mice, 156, 157, 169

- Targeted ablation, 228, 228
- Gonadotropins, *see also* Luteinizing hormone and follicle-stimulating hormone
 - Cell lines, 223
 - Common α -subunit promoter mapping, 219–222
 - Common α -subunit promoter regulation, 222, 223
 - Common α -subunit promoter placental expression, 220, 221
 - Gene knock-out of common α -subunit, 180, 228, 229
- Gonadotropin receptors and signaling, 281, 324–326
- Gonadotropin-releasing hormone (GnRH)
 - Gene deletion and hypogonadism, 168
 - GN and GT-1 cell lines, 223
- Granulosa cells
 - Development in follicle, 240
 - Gene expression during estrous cycle, 284
 - Steroidogenic enzymes, 242
- Growth defects
 - Laron syndrome in humans 8, 9
 - Gene mutations in animal models, 70, 71
- Growth hormone (GH)
 - Clinical antagonists, 11
 - Deficiency, 9–11, 70, 71
 - Developmental expression, 67, 68
 - Genes activated by GH, 7, 8
 - Peptide and nonpeptide mimetics 11, 12
 - Promoter and modulation by Pit-1, 75, 76
 - Target tissues, 2
 - Variant in placenta, 309
- Growth hormone releasing hormone (GHRH, or GRF), 1
 - GHRH expression in placenta, 314
 - GHRH receptor mutation, 9, 10
- Growth hormone releasing peptide (GHRP), 1
- Growth hormone receptor
 - Antagonist, 11
 - Defects, 9–11
 - Dimerization, 3, 4
 - Gene knock-out in mouse model, 10, 11
 - Gene knock-out comparison with STAT5 knock-out, 10
 - Signal termination, 8
 - Signaling through JAK/STAT pathway, 4, 5

Signaling through MAPK pathway, 5–7
Structure, 2, 3

H

Homeobox genes

Gene knock-outs and reproductive deficiencies, 177, 178, 191, 192

LIM homeobox genes, 177, 178

Hypopituitarism and Pit-1 mutations, 70, 71

Human chorionic gonadotropin (hCG) subunit genes and expression in placenta, 310, 311

Hypothalamus

Development, 170

Development, SF-1 and Dax-1 expression, 156–159, 175, 176

Gene knock-out models and deficiencies in reproductive function, 169, 175–177, 194

I

Inducible cAMP early repressor (ICER)

Alternate splicing product, 282, 283

Comparison to testicular I-CREB, 331

Expression in ovary, 295, 296

Regulation of inhibin gene in ovary, 297, 298

Infertility, *see* reproductive deficiencies

Inhibin

Expression in ovary and regulation by gonadotropins, 288–290

Gene knock-outs, 182–185, 195–197

Promoter regulation by cAMP, CREB, ICER, 296–298

Subunit gene promoters, 290, 291

Subunit gene structures, 286

Insulin

Cell-specific effects, 28–30

Secretion and signaling modulation, 31

Stimulation of gene activities, 47

Insulin-like growth factor-1 (IGF-1)

Decreased levels in growth hormone deficiency, 10

Gene knock-out mouse model, 185, 186

Role in ovarian development, 250–254

Stimulation of gene activities, 47

Insulin-like growth factor receptor,

association with insulin receptor, 28, 29

Insulin receptor

Autophosphorylation, 18

Recruitment of distal signaling molecules, 18–20

Signaling through SH2 and SH3 domain proteins, 20, 21

Signaling and protein tyrosine phosphatases, 21, 22

Signaling pathways through PI3K and ras-dependent pathways and glucose transport, 22–28

Structure and dimerization, 18, 19

Insulin receptor substrate (IRS) proteins, 20–23, 29, 31

IRS-1 gene knock-out, 23

IRS-1 phosphorylation by growth hormone, 6

IRS-3 and major role in in vivo metabolic signaling 23–25

Insulin resistance

Decreased tyrosine phosphatase activity in obesity and diabetes, 21, 22

Insulin receptor mutations, 23

IRS gene knock-out and overexpression, 23

L

Luteinizing hormone (LH)

LH hypersecretion in ER α knock-out mice, 187

LH hypersecretion in polycystic ovarian disease, 230, 231

Luteinizing hormone β gene

Gene regulation, 223, 225

Promoter structures, 224

Requirement for LIM proteins, 177, 217

Requirement for SF-1, 178, 224, 225

O

Ovarian cancer

Ets transcription factors, 52

Ovarian failure

Zfx gene model, 193

Ovarian follicle

Checkpoints revealed by gene disruption, 240

Developmental stages, 240, 241

Development in rat model, 278, 279

- Time-dependent expression of steroidogenic enzymes and hormones, 253
- Ovarian gene disruption effects
 - Corpus luteum, 266, 267
 - Early follicle organization, 259, 260
 - Gametogenesis, 258, 259
 - Large antral and Graafian follicles, 261–263
 - Luteinizing hormone-responsive follicle, 263
 - Ovulation, 263–265
 - Tertiary follicle, 260, 261
 - Zona pellucida, 265
- Ovary growth factors, 254–258
- P**
- Pancreas
 - Pancreatic cancer and Ets transcription factors, 52
- Pit-1 (also called GHF-1)
 - Expression in pituitary development and specific cell types, 68, 69
 - Expression in placenta, 315
 - Mutations and hormone deficiencies, 9, 70, 71
 - Pit-1 gene expression and modulation, 73–75
 - Regulation of specific pituitary genes, 73–81
 - Structure and function, 69, 70
 - Variant expression and effects on gene transcription, 71–73
- Pituitary, *see* anterior pituitary
- Placental lactogen I expression and transcription, 308, 309
- Placental lactogen I promoter, 314, 316
- Placental lactogen II expression, 308, 309
- Placental trophoblast transcription factors, 314–316
- Polycystic ovarian syndrome (PCOS)
 - LH hypersecretion, 230, 231
- Pregnancy-specific glycoproteins in placenta, 312, 313
- Progesterone receptor
 - Gene knock-out models, 188, 189, 195, 411
 - Gene disruption and ovarian development, 240
 - Isoform structures, 409
 - Isoform expression, 417
 - Phosphorylation and ligand-independent activation, 397–400
- Prolactin
 - Expression in developing pituitary, 67, 68
 - Gene knock-out mouse model, 181, 195
 - Modulation by GHF-1/Pit-1, 44–48, 76, 77
 - Promoter structure, 42, 43
 - Regulation by Ets factors, 44–46
 - Regulation by growth factors, 46–48
- Prolactin receptor gene knock-out mouse model, 181, 197, 263
- Proliferin expression in placenta, 308, 309
- Prophet of Pit-1 (Prop-1)
 - Gene expression, 70
 - Mutations in humans with combined hormone deficiency, 71
- Prostaglandins and ovarian function, 266, 267
- Prostaglandin synthesis and COX2 gene, 245, 264
- Prostate cancer
 - Androgen receptor expression levels, 360
 - Androgen receptor mutations, 386–388
 - Androgen receptor polymorphisms, 361
 - Ets transcription factors, 55
- R**
- Retinoic acid receptor family
 - Gene knock-out models and infertility, 189, 190, 196
 - Heterodimers with thyroid hormone receptors, 136, 138
- Reproductive deficiencies
 - Enzyme deficiencies and female reproduction, 205–208
 - Enzyme deficiencies and sperm function, 204, 205
 - Gene knock-out models affecting both sexes, 197, 198, 245
 - Gene knock-out models affecting only females, 195, 244
 - Gene knock-out models affecting only males, 196, 198
 - Naturally occurring mutations, 168
- S**
- Selective estrogen receptor modulators (SERMS), 408, *see also* Antiestrogens
- Sertoli cells

- Hormonal sensitivity and spermatogenesis, 329
 - Mullerian inhibiting substance, 352
 - Spermatogenesis
 - Control by cAMP signaling, 329
 - Stages, 323, 324
 - Spinal bulbar muscular atrophy, 386, 387
 - Steroid 5 α -reductase enzymes
 - Isoforms and expression, 375, 376
 - Deficiency and male genital development, 376–378
 - Gene knock-out models, 378
 - Steroidogenic acute regulatory protein (StAR)
 - Activity, 248
 - Cellular location, 246
 - Expression patterns in ovary, 253
 - Gene mutations and knock-outs, 251, 252
 - Steroidogenic enzymes, 247, 250
 - Steroidogenic factor-1 (SF-1)
 - Endocrine organ developmental role, 158–160
 - Gene inactivation in mouse models, dysfunction of adrenal, pituitary, and gonads, 155–157, 172, 175, 192
 - Repression by DAX-1 interactions, 162, 163, 172
 - Structure, 154, 162
 - Synergy by interactions with Egr-1 and WT-1, 161, 162
 - Transcriptional targets, 160, 162
 - Steroid receptors
 - Binding of agonist versus antagonist, 346
 - Coactivators and corepressors, 346–349
 - Interaction with nuclear matrix, 89
 - Mechanism of ligand-independent activation, 400, 401
 - Nucleus-cytoplasmic shuttling, 88, 89
 - Structure, 100, 409
 - Structure of DNA binding domains, 344, 345
 - Structural comparison of ligand-binding domains, 347
 - Steroid receptor coactivators, 108–112, 346–349, 383–386, 420
 - Amplified in breast cancer-1 (AIB-1), 109, 112, 139, 412, 420
 - ARA70, 348, 349, 420
 - General structure, 109
 - General function, 109, 140, 381
 - Glucocorticoid receptor interacting protein-1 (GRIP-1), 109, 381, 420
 - SRC-1 gene knock-out, 189, 420
 - Steroid receptor coactivator-1 (SRC-1), 108–110, 126, 139, 348, 381, 420, 421
 - Steroid receptor corepressors
 - General function, 107, 141, 108, 382
 - Nuclear receptor corepressor (NCOR), 107, 108, 126, 141, 346, 382, 421
 - Silencing mediator for retinoid and thyroid hormone receptors (SMRT), 107, 108, 126, 346, 381
 - SMRT splicing variants, 141
 - Signal transducers and activators of transcription (STATs)
 - Cytokine and peptide hormone receptor signaling, 4, 5
 - Gene knock-outs, 10, 195
- ## T
- Testes
 - Androgen production, 352
 - Development, 156–160, 170–172, 353, 353
 - Spermatogenesis, 324
 - Testicular feminization, 353
 - Androgen receptor mutations and phenotypes, 168, 353, 357, 358, 383
 - Theca cells
 - Development in ovarian follicle, 240
 - Steroidogenic enzyme, 252
 - Thyroid hormone
 - Biological activities, 99, 119
 - Brain development, 121–123
 - Mechanism of action, 100, 106, 110
 - Thyroid hormone receptors (TRs)
 - Basal repression by unliganded receptors, 107, 108
 - Binding to DNA with accessory proteins, 104–106
 - Expression in amphibian metamorphosis, 123, 124
 - Expression in brain development, 121–123
 - Heterodimers with RXR, 138, 139
 - Homodimers, 138
 - Interactions with coactivators, 108, 110, 126, 139, 140
 - Interactions with corepressors, 107, 126, 138–140

- Isoforms
 - Gene inactivation of TR α , 128–130, 137
 - Gene inactivation of TR β , 127, 128, 130, 137
 - Structure and biological activities, 101–103, 130, 137
 - Tissue-specific expression and regulation, 103, 119–123
 - Ligand-dependent transcriptional activation, 108–111
 - Mutations, 125–127
 - Mutations and models of thyroid hormone resistance, 127–129
 - Phosphorylation and cross-talk, 106, 107, 137, 396
 - Response elements, 103, 104, 135, 138
 - Response elements and negative regulation by thyroid hormone, 135, 142, 143
 - Regulation of expression by thyroid hormones, 124
 - Suppression of transcription, 142, 143
 - Structure, 100, 136
 - Thyroid hormone resistance (RTH syndrome)
 - Animal models, 127–130
 - Clinical implications and molecular basis for central RTH, 143, 144
 - Molecular basis for phenotypic heterogeneity, 126, 127
 - Pituitary-specific resistance, 123, 144
 - Syndrome characteristics, 119, 125
 - Thyroid hormone receptor mutations and dominant negative receptors, 125, 143–145
 - Thyroid hormone receptor interactions with coactivators and corepressors, 126
 - Thyroid-stimulating hormone (TSH, or thyrotropin)
 - Expression during development, 67, 68, 77
 - TSH β subunit gene, 77–80
 - Pit-1 and GATA-2 interactions, 78–80
 - Stimulation by Pit-1 variants, 72
 - Stimulation by TRH and phorbol esters, 80
 - Suppression of subunit genes by thyroid hormones, 142, 143
 - Thyrotropes
 - Development in pituitary, 67, 68, 77
 - Specific Pit-1 variant, 71, 72
 - Thyrotrope model systems
 - α TSH cells, 68, 80
 - TtT97 thyrotropic tumor cells, 69, 77–79
 - Transforming growth factor- β family members and activity, 182–185
 - Transgenic animal technology (*see also* Gene knock-out technology), 217–219
 - Trophoblast-specific helix-loop-helix proteins, 4, 314, 315
- U**
- Uterine expression of progesterone receptors, 411
- W**
- Wilms' tumor 1 gene, 161, 162
 - Wilms' tumor gene in gonadal development, 192, 193
- Z**
- Zfx gene in ovarian failure, 183
 - Zona pellucida, 265

Gene Engineering in Endocrinology

Edited by

Margaret A. Shupnik

*University of Virginia Health Sciences Center
Charlottesville, VA*

Recent advances in genetic engineering and molecular biology have made it possible to disrupt specific genes in order to determine and better understand their function and clinical significance. In *Gene Engineering in Endocrinology*, Margaret Shupnik and a team of leading investigators review the most recent breakthroughs, emphasizing how studies of natural mutations and gene knockouts have illuminated endocrine processes. Using both animal and human model data, these authoritative researchers examine in depth the molecular basis of development, growth, and reproductive processes, the specific mutations that explain certain genetic syndromes, the hormonal regulation of gene expression (which affects the treatment of infertility and steroid-dependent cancers), and current research directions. When possible, molecular studies are compared with naturally occurring human and animal gene mutations to establish the difference between complete elimination of, or an altered, gene function.

Comprehensive and up-to-date, *Gene Engineering in Endocrinology* offers today's experimental and clinical endocrinologists, as well as reproductive biologists, a richly informative survey of what has already been accomplished with the genetic engineering of hormone processes and hormone-related genetic syndromes—research that promises powerful new experimental and therapeutic opportunities as this field continues its rapid development.

FEATURES

- The cutting edge in molecular endocrine research
- Extensive listings of gene knockouts and phenotypes for development, reproduction, and metabolism
- Gene knockouts and mutations that mimic endocrine disease
- The latest understanding of how hormones act within their target cells
- Potential targets for controlling, mimicking, or modifying hormone effects on target cells
- New insights into differentiating between problems in male/female reproduction

CONTENTS

Part I Growth, Development, and Metabolism. Differential Cell Signaling and Gene Activation by the Human Growth Hormone Receptor: *From Cell Surface to Cell Nucleus*. Insulin Action: *Molecular Mechanisms and Determinants of Specificity*. Ets Transcription Factors: *Nuclear Integrators of Signaling Pathways Regulating Endocrine Gene Expression and Carcinogenesis*. Pit-1 Expression, Regulation, and Modulation of Multiple Pituitary Genes. Subnuclear Trafficking of Glucocorticoid Receptors: *General Mechanisms and Specific Recruitment to a Unique Target Site by Tethering to a DNA-Bound POU Domain Protein*. Thyroid Hormone Receptors and Their Multiple Transcriptional Roles. Models of Resistance to Thyroid Hormone. Thyroid Hormone Receptor Family Members: *Homodimers, Heterodimers, and Mechanisms of Transcriptional Repression*. SF-1 and DAX-1: *A Dynamic Duo in Endocrine Development*. **Part II Reproductive System.** Gene Knockout Models to Study the Hypothalamus-Pituitary-Gonadal Axis. Transgenic Approaches to Study Developmental Expression and

Regulation of the Gonadotropin Genes. Molecular Events Defining Follicular Developments and Steroidogenesis in the Ovary. Regulation of Inhibin Subunit Gene Expression by Gonadotropins and cAMP in Ovarian Granulosa Cells. Placental Trophoblast Cells: *Transcriptional Regulation and Differentiation*. Alternative Splicing of mRNAs for cAMP-Responsive Transcriptional Factors and Modulation of Transcription in the Testis. The Androgen Receptor, Androgen Insensitivity, and Prostate Cancer: *Genetic Determination of Androgen Responsiveness*. Steroid Receptor Regulation by Phosphorylation and Cell Signaling Pathways. Steroid Receptor Actions: *Agonists and Antagonists and the Role of Coactivators and Corepressors*. Index.





<http://www.springer.com/978-0-89603-718-2>

Gene Engineering in Endocrinology

Shupnik, M.A. (Ed.)

2000, XII, 428 p., Hardcover

ISBN: 978-0-89603-718-2

A product of Humana Press